Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyBiologicalProcess	homophilic cell adhesion via plasma membrane adhesion molecules	CEACAM5 CEACAM6 CADM2 CEACAM1 HMCN2 NECTIN1 PKD1 ROBO3 PCDHGC5 PCDHGB1 FAT3 PCDH11Y	4.58e-07	187	208	12	GO:0007156
GeneOntologyBiologicalProcess	cell-cell adhesion via plasma-membrane adhesion molecules	CEACAM5 CEACAM6 WNK1 CADM2 CEACAM1 HMCN2 LRFN5 NECTIN1 PKD1 ROBO3 PCDHGC5 PCDHGB1 FAT3 PCDH11Y GRID2	7.22e-07	313	208	15	GO:0098742
GeneOntologyBiologicalProcess	cell junction organization	EPHB2 CEACAM5 ASIC2 ADGRB3 CEACAM6 ACTN2 CEACAM1 NRP1 NEDD4 PARD6B NF1 HMCN2 LRFN5 NECTIN1 CLDN34 PLEKHA7 SHANK1 PCDHGC5 PPP1R9A GRID2 TEK NCAN DOCK7 VHLL TMEM108 AGRN	5.92e-06	974	208	26	GO:0034330
GeneOntologyCellularComponent	Golgi lumen	F8 BPNT2 MUCL1 MUC5B VCAN NCAN CSPG4 AGRN MUC6 PROS1	1.45e-07	109	209	10	GO:0005796
GeneOntologyCellularComponent	glutamatergic synapse	EPHB2 MAP2 ADGRB3 ACTN2 NRP1 NEDD4 NF1 LRFN5 SHANK1 CACNA2D1 PPP1R9A GRID2 RPSA GABBR2 P2RX6 NCAN VHLL PRKCE TMEM108 AGRN	2.14e-04	817	209	20	GO:0098978
GeneOntologyCellularComponent	postsynaptic membrane	EPHB2 ASIC2 ADGRB3 ACTN2 NRP1 LRFN5 SHANK1 CACNA2D1 ANK1 GRID2 GABBR2 P2RX6 TMEM108	2.32e-04	405	209	13	GO:0045211
GeneOntologyCellularComponent	somatodendritic compartment	EPHB2 MAP2 ASIC2 CYP17A1 SREBF2 ACTN2 CADM2 PGR NRP1 NEDD4 NF1 HMCN2 NECTIN1 AGFG1 SHANK1 FLNB FAT3 PPP1R9A GRID2 RPSA CIT P2RX6 TMEM108 WDFY3 EPHA10 EPHA8	2.46e-04	1228	209	26	GO:0036477
GeneOntologyCellularComponent	RAVE complex	DMXL1 DMXL2	2.96e-04	3	209	2	GO:0043291
GeneOntologyCellularComponent	extracellular matrix	FREM2 FBLN1 FCGBP HMCN2 COL21A1 ECM2 ANXA7 COL5A3 RPSA MUC5B TECTA TIMP1 VCAN NCAN CSPG4 AGRN MUC6	3.37e-04	656	209	17	GO:0031012
GeneOntologyCellularComponent	external encapsulating structure	FREM2 FBLN1 FCGBP HMCN2 COL21A1 ECM2 ANXA7 COL5A3 RPSA MUC5B TECTA TIMP1 VCAN NCAN CSPG4 AGRN MUC6	3.49e-04	658	209	17	GO:0030312
GeneOntologyCellularComponent	lysosomal lumen	LAMP2 CUBN VCAN NCAN CSPG4 AGRN	4.56e-04	98	209	6	GO:0043202
GeneOntologyCellularComponent	transforming growth factor beta ligand-receptor complex	CEACAM5 CEACAM6 CEACAM1	5.01e-04	16	209	3	GO:0070021
GeneOntologyCellularComponent	axon	EPHB2 MAP2 CYP17A1 CADM2 PGR NRP1 NF1 HMCN2 SYNJ2 NECTIN1 ROBO3 ANK1 PCDHGB1 PPP1R9A LGI3 SBF2 DOCK7 TMEM108 WDFY3 AGRN	6.46e-04	891	209	20	GO:0030424
GeneOntologyCellularComponent	dendritic spine	EPHB2 ASIC2 ACTN2 PGR NEDD4 SHANK1 PPP1R9A GRID2 P2RX6	7.65e-04	242	209	9	GO:0043197
GeneOntologyCellularComponent	neuron spine	EPHB2 ASIC2 ACTN2 PGR NEDD4 SHANK1 PPP1R9A GRID2 P2RX6	8.84e-04	247	209	9	GO:0044309
GeneOntologyCellularComponent	apical plasma membrane	CEACAM5 CEACAM6 MFSD4B CEACAM1 PARD6B UPK3A ABCG2 NAALADL1 SLC2A9 CUBN TEK CSPG4 OSMR	1.29e-03	487	209	13	GO:0016324
GeneOntologyCellularComponent	cell projection membrane	CEACAM5 MAP2 CEACAM6 CEACAM1 SYNJ2 PKD1 ABCG2 ANK1 DOCK8 CUBN APPL2 CSPG4	1.39e-03	431	209	12	GO:0031253
GeneOntologyCellularComponent	basement membrane	FREM2 FBLN1 HMCN2 RPSA TIMP1 AGRN	1.44e-03	122	209	6	GO:0005604
Domain	Ig-like_fold	EPHB2 IGFN1 CEACAM5 CEACAM6 CADM2 CEACAM1 IGSF10 PTPRB HMCN2 PIGR NOMO2 LRFN5 NECTIN1 ROBO3 FLNB TEK ATF7IP VCAN NCAN OSMR NFAT5 NOMO3 EPHA10 EPHA8	7.84e-07	706	203	24	IPR013783
Domain	-	EPHB2 IGFN1 CEACAM5 CEACAM6 CADM2 CEACAM1 IGSF10 PTPRB PIGR NOMO2 LRFN5 NECTIN1 ROBO3 FLNB TEK ATF7IP VCAN NCAN OSMR NFAT5 NOMO3 EPHA10 EPHA8	9.58e-07	663	203	23	2.60.40.10
Domain	C8	FCGBP MUC5B TECTA MUC6	6.26e-06	12	203	4	PF08742
Domain	TIL	FCGBP MUC5B TECTA MUC6	6.26e-06	12	203	4	PF01826
Domain	Unchr_dom_Cys-rich	FCGBP MUC5B TECTA MUC6	8.97e-06	13	203	4	IPR014853
Domain	C8	FCGBP MUC5B TECTA MUC6	8.97e-06	13	203	4	SM00832
Domain	-	COL21A1 FAT3 COL5A3 CSPG4 WDFY3 LRBA AGRN PROS1	9.18e-06	95	203	8	2.60.120.200
Domain	TIL_dom	FCGBP MUC5B TECTA MUC6	1.25e-05	14	203	4	IPR002919
Domain	FN3_dom	EPHB2 IGFN1 KIAA0319L PTPRB LRFN5 ROBO3 TEK ATF7IP OSMR EPHA10 EPHA8	1.87e-05	209	203	11	IPR003961
Domain	VWF_type-D	FCGBP MUC5B TECTA MUC6	2.23e-05	16	203	4	IPR001846
Domain	VWFD	FCGBP MUC5B TECTA MUC6	2.23e-05	16	203	4	PS51233
Domain	VWD	FCGBP MUC5B TECTA MUC6	2.23e-05	16	203	4	SM00216
Domain	VWD	FCGBP MUC5B TECTA MUC6	2.23e-05	16	203	4	PF00094
Domain	ConA-like_dom	TMPRSS15 RYR2 NRP1 COL21A1 FAT3 COL5A3 CSPG4 WDFY3 LRBA AGRN PROS1	2.88e-05	219	203	11	IPR013320
Domain	EGF-like_CS	ZNRF4 FBLN1 HMCN2 FAT3 CUBN TEK VCAN NCAN AGRN EPHA10 PROS1 EPHA8	2.99e-05	261	203	12	IPR013032
Domain	EGF_2	EPHB2 FBLN1 HMCN2 FAT3 CUBN TEK VCAN NCAN AGRN EPHA10 PROS1 EPHA8	3.47e-05	265	203	12	PS01186
Domain	Laminin_G	COL21A1 FAT3 COL5A3 CSPG4 AGRN PROS1	3.87e-05	58	203	6	IPR001791
Domain	VWC_out	FCGBP MUC5B TECTA MUC6	4.62e-05	19	203	4	SM00215
Domain	EGF_CA	FBLN1 HMCN2 FAT3 CUBN VCAN NCAN AGRN PROS1	5.67e-05	122	203	8	SM00179
Domain	EGF-like_Ca-bd_dom	FBLN1 HMCN2 FAT3 CUBN VCAN NCAN AGRN PROS1	6.36e-05	124	203	8	IPR001881
Domain	FN3	EPHB2 IGFN1 PTPRB LRFN5 ROBO3 TEK ATF7IP OSMR EPHA10 EPHA8	6.63e-05	199	203	10	PS50853
Domain	VWF_dom	FCGBP ECM2 MUC5B TECTA MUC6	8.86e-05	42	203	5	IPR001007
Domain	EGF_Ca-bd_CS	FBLN1 HMCN2 FAT3 CUBN VCAN NCAN PROS1	9.08e-05	97	203	7	IPR018097
Domain	EGF-like_dom	FBLN1 FCGBP HMCN2 FAT3 CUBN TECTA TEK VCAN NCAN AGRN PROS1	9.19e-05	249	203	11	IPR000742
Domain	EGF_CA	FBLN1 HMCN2 FAT3 CUBN VCAN NCAN PROS1	1.03e-04	99	203	7	PS01187
Domain	ASX_HYDROXYL	FBLN1 HMCN2 FAT3 CUBN VCAN NCAN PROS1	1.10e-04	100	203	7	PS00010
Domain	LamG	FAT3 COL5A3 CSPG4 AGRN PROS1	1.11e-04	44	203	5	SM00282
Domain	Rav1p_C	DMXL1 DMXL2	1.18e-04	2	203	2	IPR022033
Domain	Rav1p_C	DMXL1 DMXL2	1.18e-04	2	203	2	PF12234
Domain	-	EPHB2 F8 NRP1 XRCC1 EPHA10 EPHA8	1.42e-04	73	203	6	2.60.120.260
Domain	EGF-type_Asp/Asn_hydroxyl_site	FBLN1 HMCN2 FAT3 CUBN VCAN NCAN PROS1	1.59e-04	106	203	7	IPR000152
Domain	Laminin_G_1	CSPG4 AGRN PROS1	1.96e-04	11	203	3	PF00054
Domain	FN3	EPHB2 IGFN1 KIAA0319L PTPRB ROBO3 TEK OSMR EPHA10 EPHA8	1.96e-04	185	203	9	SM00060
Domain	Ig_I-set	IGFN1 CEACAM5 CEACAM6 CADM2 CEACAM1 IGSF10 HMCN2 LRFN5 ROBO3	2.39e-04	190	203	9	IPR013098
Domain	I-set	IGFN1 CEACAM5 CEACAM6 CADM2 CEACAM1 IGSF10 HMCN2 LRFN5 ROBO3	2.39e-04	190	203	9	PF07679
Domain	EGF	FBLN1 FCGBP FAT3 CUBN TECTA TEK VCAN NCAN AGRN PROS1	2.59e-04	235	203	10	SM00181
Domain	IGc2	IGFN1 CEACAM5 CEACAM6 CADM2 CEACAM1 IGSF10 HMCN2 LRFN5 NECTIN1 ROBO3	2.59e-04	235	203	10	SM00408
Domain	Ig_sub2	IGFN1 CEACAM5 CEACAM6 CADM2 CEACAM1 IGSF10 HMCN2 LRFN5 NECTIN1 ROBO3	2.59e-04	235	203	10	IPR003598
Domain	CUB	TMPRSS15 ADGRB3 NRP1 CUBN CDCP1	2.71e-04	53	203	5	PS01180
Domain	Ig_V-set	CEACAM5 CEACAM6 CADM2 CEACAM1 IGSF10 PIGR NECTIN1 VCAN NCAN	3.37e-04	199	203	9	IPR013106
Domain	TILa_dom	FCGBP TECTA	3.50e-04	3	203	2	IPR025615
Domain	TILa	FCGBP TECTA	3.50e-04	3	203	2	PF12714
Domain	CUB_dom	TMPRSS15 ADGRB3 NRP1 CUBN CDCP1	3.82e-04	57	203	5	IPR000859
Domain	fn3	EPHB2 IGFN1 PTPRB ROBO3 TEK OSMR EPHA10 EPHA8	4.02e-04	162	203	8	PF00041
Domain	RECEPTOR_TYR_KIN_V_2	EPHB2 EPHA10 EPHA8	4.22e-04	14	203	3	PS00791
Domain	RECEPTOR_TYR_KIN_V_1	EPHB2 EPHA10 EPHA8	4.22e-04	14	203	3	PS00790
Domain	Tyr_kinase_rcpt_V_CS	EPHB2 EPHA10 EPHA8	4.22e-04	14	203	3	IPR001426
Domain	EphA2_TM	EPHB2 EPHA10 EPHA8	4.22e-04	14	203	3	PF14575
Domain	Ephrin_rcpt_lig-bd_dom	EPHB2 EPHA10 EPHA8	4.22e-04	14	203	3	IPR001090
Domain	Eph_TM	EPHB2 EPHA10 EPHA8	4.22e-04	14	203	3	IPR027936
Domain	EPH_lbd	EPHB2 EPHA10 EPHA8	4.22e-04	14	203	3	SM00615
Domain	Ephrin_lbd	EPHB2 EPHA10 EPHA8	4.22e-04	14	203	3	PF01404
Domain	Tyr_kinase_ephrin_rcpt	EPHB2 EPHA10 EPHA8	4.22e-04	14	203	3	IPR016257
Domain	EPH_LBD	EPHB2 EPHA10 EPHA8	4.22e-04	14	203	3	PS51550
Domain	Galactose-bd-like	EPHB2 F8 NRP1 XRCC1 EPHA10 EPHA8	5.64e-04	94	203	6	IPR008979
Domain	DUF2012	NOMO2 NOMO3	6.95e-04	4	203	2	PF09430
Domain	DUF2012	NOMO2 NOMO3	6.95e-04	4	203	2	IPR019008
Domain	IG	IGFN1 CEACAM5 CEACAM6 CADM2 CEACAM1 IGSF10 HMCN2 PIGR LRFN5 NECTIN1 ROBO3 VCAN NCAN	7.28e-04	421	203	13	SM00409
Domain	Ig_sub	IGFN1 CEACAM5 CEACAM6 CADM2 CEACAM1 IGSF10 HMCN2 PIGR LRFN5 NECTIN1 ROBO3 VCAN NCAN	7.28e-04	421	203	13	IPR003599
Domain	VWC	FCGBP ECM2 MUC5B TECTA	7.49e-04	38	203	4	SM00214
Domain	LAM_G_DOMAIN	FAT3 CSPG4 AGRN PROS1	7.49e-04	38	203	4	PS50025
Domain	ZP_dom	ZPLD1 TECTA ENG	7.69e-04	17	203	3	IPR001507
Domain	Zona_pellucida	ZPLD1 TECTA ENG	7.69e-04	17	203	3	PF00100
Domain	PDZ	PARD6B AHNAK SHANK1 PPP1R9A HTRA3 SDCBP2 AHNAK2	8.95e-04	141	203	7	PF00595
Domain	Laminin_G_2	FAT3 COL5A3 CSPG4 PROS1	9.12e-04	40	203	4	PF02210
Domain	V-set	CEACAM5 CEACAM6 CADM2 CEACAM1 PIGR NECTIN1 VCAN NCAN	9.28e-04	184	203	8	PF07686
Domain	IG_LIKE	IGFN1 CEACAM5 CEACAM6 CADM2 CEACAM1 IGSF10 HMCN2 PIGR LRFN5 NECTIN1 ROBO3 TEK VCAN NCAN	9.93e-04	491	203	14	PS50835
Domain	AAA	WRNIP1 ABCA8 ABCG4 ABCG2 DNAH2 RUVBL1 HELZ2	1.01e-03	144	203	7	SM00382
Domain	AAA+_ATPase	WRNIP1 ABCA8 ABCG4 ABCG2 DNAH2 RUVBL1 HELZ2	1.01e-03	144	203	7	IPR003593
Domain	PA	ZNRF4 RNF150 NAALADL1	1.08e-03	19	203	3	PF02225
Domain	PA_domain	ZNRF4 RNF150 NAALADL1	1.08e-03	19	203	3	IPR003137
Domain	EGF_3	FBLN1 HMCN2 FAT3 CUBN TEK VCAN NCAN AGRN PROS1	1.11e-03	235	203	9	PS50026
Domain	WSC	PKD1 WSCD1	1.15e-03	5	203	2	SM00321
Domain	ZnF_Rad18	WRNIP1 POLK	1.15e-03	5	203	2	SM00734
Domain	TMEM132D_N	TMEM132D TMEM132E	1.15e-03	5	203	2	PF15705
Domain	TMEM132D_C	TMEM132D TMEM132E	1.15e-03	5	203	2	PF15706
Domain	TMEM132_M	TMEM132D TMEM132E	1.15e-03	5	203	2	IPR031437
Domain	TMEM132_C	TMEM132D TMEM132E	1.15e-03	5	203	2	IPR031436
Domain	TMEM132_N	TMEM132D TMEM132E	1.15e-03	5	203	2	IPR031435
Domain	WSC	PKD1 WSCD1	1.15e-03	5	203	2	PS51212
Domain	TMEM132	TMEM132D TMEM132E	1.15e-03	5	203	2	IPR026307
Domain	ABC2_membrane	ABCG4 ABCG2	1.15e-03	5	203	2	PF01061
Domain	TMEM132	TMEM132D TMEM132E	1.15e-03	5	203	2	PF16070
Domain	WSC_carb-bd	PKD1 WSCD1	1.15e-03	5	203	2	IPR002889
Domain	WSC	PKD1 WSCD1	1.15e-03	5	203	2	PF01822
Domain	ABC_2_trans	ABCG4 ABCG2	1.15e-03	5	203	2	IPR013525
Domain	DUF4704	WDFY3 LRBA	1.15e-03	5	203	2	IPR031570
Domain	DUF4704	WDFY3 LRBA	1.15e-03	5	203	2	PF15787
Domain	Znf_Rad18_put	WRNIP1 POLK	1.15e-03	5	203	2	IPR006642
Domain	PDZ	PARD6B AHNAK SHANK1 PPP1R9A HTRA3 SDCBP2 AHNAK2	1.19e-03	148	203	7	SM00228
Domain	Ig-like_dom	IGFN1 CEACAM5 CEACAM6 CADM2 CEACAM1 IGSF10 HMCN2 PIGR LRFN5 NECTIN1 ROBO3 TEK VCAN NCAN	1.25e-03	503	203	14	IPR007110
Domain	-	PARD6B AHNAK SHANK1 PPP1R9A HTRA3 SDCBP2 AHNAK2	1.28e-03	150	203	7	2.30.42.10
Domain	PDZ	PARD6B AHNAK SHANK1 PPP1R9A HTRA3 SDCBP2 AHNAK2	1.33e-03	151	203	7	PS50106
Domain	PDZ	PARD6B AHNAK SHANK1 PPP1R9A HTRA3 SDCBP2 AHNAK2	1.39e-03	152	203	7	IPR001478
Domain	Growth_fac_rcpt_	EPHB2 FBLN1 HMCN2 HTRA3 CUBN TEK PROS1	1.61e-03	156	203	7	IPR009030
Domain	PH_BEACH	WDFY3 LRBA	1.71e-03	6	203	2	PF14844
Domain	DUF3398	DOCK8 DOCK7	1.71e-03	6	203	2	PF11878
Domain	PKD/REJ-like	KIAA0319L PKD1	1.71e-03	6	203	2	IPR002859
Domain	REJ	KIAA0319L PKD1	1.71e-03	6	203	2	PF02010
Domain	DOCK_C/D_N	DOCK8 DOCK7	1.71e-03	6	203	2	IPR021816
Pathway	REACTOME_DEFECTIVE_B4GALT7_CAUSES_EDS_PROGEROID_TYPE	VCAN NCAN CSPG4 AGRN	5.65e-05	20	153	4	M27258
Pathway	REACTOME_DEFECTIVE_CHST14_CAUSES_EDS_MUSCULOCONTRACTURAL_TYPE	VCAN NCAN CSPG4	6.75e-05	8	153	3	M27260
Pathway	REACTOME_DEFECTIVE_CHSY1_CAUSES_TPBS	VCAN NCAN CSPG4	6.75e-05	8	153	3	M27261
Pathway	REACTOME_DEFECTIVE_CHST3_CAUSES_SEDCJD	VCAN NCAN CSPG4	6.75e-05	8	153	3	M27259
Pathway	REACTOME_A_TETRASACCHARIDE_LINKER_SEQUENCE_IS_REQUIRED_FOR_GAG_SYNTHESIS	VCAN NCAN CSPG4 AGRN	1.66e-04	26	153	4	M708
Pathway	REACTOME_DERMATAN_SULFATE_BIOSYNTHESIS	VCAN NCAN CSPG4	1.94e-04	11	153	3	M27105
Pubmed	Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.	CD109 F8 CEACAM1 NRP1 FREM2 FCGBP PIGR NECTIN1 CACNA2D1 LAMP2 TIMP1 CSPG4 SERPIND1 PROS1	7.14e-10	257	211	14	16335952
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	ADGRB3 NCL EMSY NEDD4 NF1 AGO3 EXOG MGA SHANK1 CACNA2D1 DMXL2 PPP1R9A NOL9 GABBR2 XRCC5 CIT ATF7IP NCAN DOCK7 UBA6 CCAR1 PRKCE WDFY3 AGRN	5.79e-09	963	211	24	28671696
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	GAK MAP2 WRNIP1 NCL ACTN2 CADM2 IGHV1-69D CSDE1 NF1 PLEKHA7 TARS1 SHANK1 FLNB CACNA2D1 DMXL2 HSPA4L DOCK8 IGHV1-69 PPP1R9A RPSA CIT APPL2 LGI3 VCAN NCAN DOCK7 LRRCC1 PRKCE	5.25e-08	1431	211	28	37142655
Pubmed	A human MAP kinase interactome.	SREBF2 NCL WNK1 CSDE1 PARD6B TSC22D1 SYNJ2 SIMC1 AGFG1 USF2 MGA COG4 SHANK1 ANXA7 ATF7IP PRKCE	5.63e-08	486	211	16	20936779
Pubmed	ESCPE-1 mediates retrograde endosomal sorting of the SARS-CoV-2 host factor Neuropilin-1.	EPHB2 RPN2 KIAA0319L CD109 DMXL1 NRP1 CSDE1 IGSF10 BPNT2 FBLN1 FOXRED2 NF1 NOMO2 CACNA2D1 HSPA4L LAMP2 PAICS RUVBL1 TIMP1 LPCAT3 CSPG4 OSMR ENG AGRN PROS1	9.11e-08	1201	211	25	35696571
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	ZBTB20 MORN1 MAP2 SREBF2 NRP1 CSDE1 TSC22D1 PTPRB SYNJ2 FNIP1 POLK FLNB PCDHGB1 ANXA7 PPP1R9A PCDH11Y TECTA XRCC5 LPCAT3 SBF2 TTC21B UBA6 CCAR1 CDK5RAP1 PRKCE LRBA NFAT5 KDM4B	1.19e-07	1489	211	28	28611215
Pubmed	Identification of N-linked glycoproteins in human saliva by glycoprotein capture and mass spectrometry.	CEACAM5 CEACAM6 FCGBP PIGR MUC5B TIMP1	1.75e-07	41	211	6	16740002
Pubmed	In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.	CEACAM5 ACTN2 CEACAM1 NEDD4 FREM2 FBLN1 FCGBP PIGR UPK3A FLNB CACNA2D1 ANXA7 LAMP2 MUC5B CUBN VPS37B PAICS TIMP1 CSPG4 SDCBP2 AGRN SERPIND1 PROS1	1.76e-07	1070	211	23	23533145
Pubmed	Carcinoembryonic antigen-related cell adhesion molecules (CEACAM) 1, 5 and 6 as biomarkers in pancreatic cancer.	CEACAM5 CEACAM6 CEACAM1	2.20e-07	3	211	3	25409014
Pubmed	Expression of Chosen Carcinoembryonic-Related Cell Adhesion Molecules in Pancreatic Intraepithelial Neoplasia (PanIN) Associated with Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma (PDAC).	CEACAM5 CEACAM6 CEACAM1	2.20e-07	3	211	3	31171910
Pubmed	Construction of long-transcript enriched cDNA libraries from submicrogram amounts of total RNAs by a universal PCR amplification method.	CYP17A1 SREBF2 WNK1 PSME4 ZBTB40 USF2 POLK MGA PLEKHA7 COG4 NPAT FLNB DEPDC1 NOL9 CUBN CDCP1 PAICS WDHD1 VCAN SBF2 GRAMD2B NFAT5 AGRN	2.22e-07	1084	211	23	11544199
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	MORN1 KIAA0319L MAML1 WNK1 PSME4 AHNAK PKD1 WDR90 SLC52A2 ZNF628 EP400 RPSA CIT TLNRD1 ARHGEF40 C2CD3 SBF2 CSPG4 HELZ2 WDFY3 LRBA AGRN AHNAK2	3.10e-07	1105	211	23	35748872
Pubmed	The p300/YY1/miR-500a-5p/HDAC2 signalling axis regulates cell proliferation in human colorectal cancer.	WRNIP1 NCL WNK1 CSDE1 AHNAK AGFG1 TARS1 XRCC5 HELZ2 CDK5RAP1 LRBA AHNAK2	3.26e-07	298	211	12	30737378
Pubmed	Identifications of novel host cell factors that interact with the receptor-binding domain of the SARS-CoV-2 spike protein.	RPN2 SREBF2 NCL NRP1 CSDE1 FREM2 PSME4 COG4 DDX11L8 DMXL2 NOL9 ARHGEF40 ARNT DOCK7 CCAR1 CDK5RAP1 AGRN	5.55e-07	650	211	17	38777146
Pubmed	Expression of the immunoglobulin superfamily cell adhesion molecules in the developing spinal cord and dorsal root ganglion.	CEACAM5 CEACAM6 CADM2 CEACAM1 IGSF10 LRFN5 NECTIN1 ROBO3 TEK	7.11e-07	162	211	9	25826454
Pubmed	Helicobacter pylori adhesin HopQ engages in a virulence-enhancing interaction with human CEACAMs.	CEACAM5 CEACAM6 CEACAM1	8.77e-07	4	211	3	27748768
Pubmed	Helicobacter pylori exploits human CEACAMs via HopQ for adherence and translocation of CagA.	CEACAM5 CEACAM6 CEACAM1	8.77e-07	4	211	3	27748756
Pubmed	Diverse oligomeric states of CEACAM IgV domains.	CEACAM5 CEACAM6 CEACAM1	8.77e-07	4	211	3	26483485
Pubmed	Four carcinoembryonic antigen subfamily members, CEA, NCA, BGP and CGM2, selectively expressed in the normal human colonic epithelium, are integral components of the fuzzy coat.	CEACAM5 CEACAM6 CEACAM1	8.77e-07	4	211	3	10436421
Pubmed	Large-scale proteomics and phosphoproteomics of urinary exosomes.	SNX3 CEACAM5 ARL6 PARD6B FCGBP PIGR AHNAK PKD1 UPK3A PLEKHA7 FLNB CACNA2D1 ANXA7 PM20D1 LAMP2 CUBN TECTA VPS37B VPS13D APPL2 SDCBP2	1.17e-06	1016	211	21	19056867
Pubmed	Protein kinase Cε modulates insulin receptor localization and trafficking in mouse embryonic fibroblasts.	CEACAM5 CEACAM6 CEACAM1 PRKCE	1.26e-06	14	211	4	23469261
Pubmed	SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms.	CEACAM5 CEACAM6 CEACAM1 RAG2	1.26e-06	14	211	4	17081782
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	SNX3 MAP2 SEC24A WNK1 NEDD4 FSIP2 NF1 SYNJ2 AHNAK AGFG1 FNIP1 PLEKHA7 STIL VPS13D C2CD3 DOCK7 PRKCE PDCL AHNAK2	1.50e-06	861	211	19	36931259
Pubmed	CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.	CEACAM5 CEACAM6 CEACAM1 RAG2	1.71e-06	15	211	4	25363763
Pubmed	Disabled-1 acts downstream of Reelin in a signaling pathway that controls laminar organization in the mammalian brain.	MAP2 VCAN NCAN	2.18e-06	5	211	3	9716537
Pubmed	Identification of proteins associated with ligand-activated estrogen receptor α in human breast cancer cell nuclei by tandem affinity purification and nano LC-MS/MS.	RPN2 NCL DECR1 AHNAK FLNB EP400 DNAH2 RPSA VPS13D RUVBL1	2.82e-06	245	211	10	21182205
Pubmed	Identification of proximal SUMO-dependent interactors using SUMO-ID.	EMSY CSDE1 PIGR AHNAK SIMC1 POLK MGA TARS1 EP400 PPWD1 ARNT ZNF281 AHNAK2	3.70e-06	444	211	13	34795231
Pubmed	Sequence comparison of human and mouse genes reveals a homologous block structure in the promoter regions.	CEACAM5 CD109 BCL2L2 CSDE1 NF1 COL21A1 AHNAK WDR20 COG4 CACNA2D1 XRCC1 CUBN XRCC5 CREM ADGRG7 VCAN CSPG4 GRAMD2B SERTAD4 OSMR SDCBP2 ZNF281 SERPIND1	4.40e-06	1293	211	23	15342556
Pubmed	LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy.	RPN2 NCL AHNAK FLNB RPSA XRCC5 CIT ARHGEF40 DOCK7	4.40e-06	202	211	9	33005030
Pubmed	The human cytoplasmic dynein interactome reveals novel activators of motility.	SEC24A KIAA0319L MAML1 EMSY DECR1 CSDE1 AGO3 SYNJ2 NOMO2 SIMC1 MGA PLEKHA7 STIL C2CD3 RUVBL1 LRRCC1 PDCL AGRN	5.29e-06	853	211	18	28718761
Pubmed	Genome-wide association analysis of red blood cell traits in African Americans: the COGENT Network.	F8 DECR1 WDR90 PRKCE	5.91e-06	20	211	4	23446634
Pubmed	Progesterone and HMOX-1 promote fetal growth by CD8+ T cell modulation.	CEACAM5 CEACAM6 PGR CEACAM1	5.91e-06	20	211	4	25774501
Pubmed	Defining the proximal interaction networks of Arf GTPases reveals a mechanism for the regulation of PLD1 and PI4KB.	SNX3 SEC24A KIAA0319L MAML1 NCL RYR2 DMXL1 ARL6 AHNAK WDR20 MGA TARS1 EP400 ARL4C ATF7IP DOCK7 LRBA	6.09e-06	777	211	17	35844135
Pubmed	PlexinA1 signaling directs the segregation of proprioceptive sensory axons in the developing spinal cord.	EPHB2 CADM2 NRP1 LRFN5 NECTIN1 CUBN EPHA8	7.72e-06	117	211	7	17145500
Pubmed	The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices.	FREM2 FBLN1 HMCN2 ANXA7 COL5A3 VCAN CSPG4 AGRN	8.91e-06	167	211	8	22159717
Pubmed	A high-throughput approach for measuring temporal changes in the interactome.	MAP2 SEC24A WRNIP1 NCL WNK1 CSDE1 TSC22D1 PSME4 AHNAK AGFG1 TARS1 FLNB HSPA4L POLA1 LAMP2 RPSA XRCC5 PAICS APPL2 RUVBL1 WDHD1 UBA6 LRBA AHNAK2	9.52e-06	1455	211	24	22863883
Pubmed	Human variation in alcohol response is influenced by variation in neuronal signaling genes.	ASIC2 ACTN2 NRP1 PTPRB PKD1 XRCC5 PAICS VCAN	1.06e-05	171	211	8	20201926
Pubmed	N-Terminomics for the Identification of In Vitro Substrates and Cleavage Site Specificity of the SARS-CoV-2 Main Protease.	GAK EMSY CSDE1 PTPRB AHNAK FLNB PPP1R9A XRCC1 PAICS CCAR1 AHNAK2	1.41e-05	360	211	11	33111431
Pubmed	Identifying biological pathways that underlie primordial short stature using network analysis.	NCL NRP1 NF1 AHNAK MGA TARS1 FLNB CACNA2D1 EP400 PPP1R9A RPSA SCAMP3 XRCC1 XRCC5 CIT RUVBL1 DOCK7 UBA6 CKAP2L	1.75e-05	1024	211	19	24711643
Pubmed	Placental defects in ARNT-knockout conceptus correlate with localized decreases in VEGF-R2, Ang-1, and Tie-2.	NRP1 TEK ARNT	1.80e-05	9	211	3	11084652
Pubmed	Embryonic stem cell tumor model reveals role of vascular endothelial receptor tyrosine phosphatase in regulating Tie2 pathway in tumor angiogenesis.	PTPRB TEK ENG	1.80e-05	9	211	3	20018779
Pubmed	Faciogenital Dysplasia 5 supports cancer stem cell traits in basal-like breast cancer by enhancing EGFR stability.	NCL NEDD4 AHNAK FLNB RPSA PAICS DOCK7 NOMO3	2.36e-05	191	211	8	33762435
Pubmed	Extra-embryonic vasculature development is regulated by the transcription factor HAND1.	EPHB2 NRP1 TEK ENG	2.40e-05	28	211	4	15073150
Pubmed	Probing chromatin landscape reveals roles of endocardial TBX20 in septation.	ACTN2 TEK VCAN	2.56e-05	10	211	3	27348591
Pubmed	Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function.	NCL DECR1 CSDE1 NF1 PSME4 AHNAK MGA TARS1 FLNB EP400 POLA1 RPSA NOL9 XRCC5 PAICS ARHGEF40 RUVBL1 CCAR1 WDFY3 ZNF281 AGRN AHNAK2	2.84e-05	1353	211	22	29467282
Pubmed	GPR124, an orphan G protein-coupled receptor, is required for CNS-specific vascularization and establishment of the blood-brain barrier.	NRP1 TEK TIMP1 CSPG4 ENG	3.01e-05	59	211	5	21421844
Pubmed	BioID-based intact cell interactome of the Kv1.3 potassium channel identifies a Kv1.3-STAT3-p53 cellular signaling pathway.	RPN2 SEC24A CSDE1 AHNAK TARS1 FLNB HSPA4L LAMP2 XRCC5 PAICS RUVBL1 ZC3HAV1L DOCK7 UBA6 LRBA	3.14e-05	708	211	15	39231216
Pubmed	Analysis of axonal regeneration in the central and peripheral nervous systems of the NG2-deficient mouse.	VCAN CSPG4	3.66e-05	2	211	2	17900358
Pubmed	Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1.	NRP1 RAG2	3.66e-05	2	211	2	35874918
Pubmed	Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII.	F8 PROS1	3.66e-05	2	211	2	7620160
Pubmed	Bacterial protein domains with a novel Ig-like fold target human CEACAM receptors.	CEACAM5 CEACAM1	3.66e-05	2	211	2	33522633
Pubmed	A novel prognostic index in colorectal cancer defined by serum carcinoembryonic antigen and plasma tissue inhibitor of metalloproteinases-1.	CEACAM5 TIMP1	3.66e-05	2	211	2	20095885
Pubmed	Versican provides the provisional matrix for uterine spiral artery dilation and fetal growth.	PGR VCAN	3.66e-05	2	211	2	36423736
Pubmed	Associations between high factor VIII and low free protein S levels with traditional arterial thrombotic risk factors and their risk on arterial thrombosis: results from a retrospective family cohort study.	F8 PROS1	3.66e-05	2	211	2	20705334
Pubmed	ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.	ABCG4 ABCG2	3.66e-05	2	211	2	22391220
Pubmed	The RNF138 E3 ligase displaces Ku to promote DNA end resection and regulate DNA repair pathway choice.	RNF138 XRCC5	3.66e-05	2	211	2	26502055
Pubmed	Alterations in sulfated chondroitin glycosaminoglycans following controlled cortical impact injury in mice.	NCAN CSPG4	3.66e-05	2	211	2	22628090
Pubmed	Downregulation of AHNAK2 inhibits cell cycle of lung adenocarcinoma cells by interacting with RUVBL1.	RUVBL1 AHNAK2	3.66e-05	2	211	2	37349884
Pubmed	Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects.	ABCG2 SLC2A9	3.66e-05	2	211	2	32778763
Pubmed	Expression of CEACAM1 or CEACAM5 in AZ-521 cells restores the type IV secretion deficiency for translocation of CagA by Helicobacter pylori.	CEACAM5 CEACAM1	3.66e-05	2	211	2	30321907
Pubmed	Upregulation of protein S by progestins.	PGR PROS1	3.66e-05	2	211	2	17958742
Pubmed	Phenotypic screen of sixty-eight colorectal cancer cell lines identifies CEACAM6 and CEACAM5 as markers of acid resistance.	CEACAM5 CEACAM6	3.66e-05	2	211	2	38502695
Pubmed	Coexistence of autosomal dominant polycystic kidney disease type 1 and hereditary renal hypouricemia type 2: A model of early-onset and fast cyst progression.	PKD1 SLC2A9	3.66e-05	2	211	2	32166738
Pubmed	TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.	PGR TIMP1	3.66e-05	2	211	2	23881388
Pubmed	Plasma TIMP-1 and CEA as Markers for Detection of Primary Colorectal Cancer: A Prospective Validation Study Including Symptomatic and Non-symptomatic Individuals.	CEACAM5 TIMP1	3.66e-05	2	211	2	26254391
Pubmed	Oncostatin M-induced astrocytic tissue inhibitor of metalloproteinases-1 drives remyelination.	TIMP1 OSMR	3.66e-05	2	211	2	32071226
Pubmed	Association between serum uric acid related genetic loci and diabetic kidney disease in the Chinese type 2 diabetes patients.	ABCG2 SLC2A9	3.66e-05	2	211	2	26993665
Pubmed	Gout in Older Adults: The Atherosclerosis Risk in Communities Study.	ABCG2 SLC2A9	3.66e-05	2	211	2	26714568
Pubmed	CEACAM engagement by human pathogens enhances cell adhesion and counteracts bacteria-induced detachment of epithelial cells.	CEACAM6 CEACAM1	3.66e-05	2	211	2	16115956
Pubmed	Genetic polymorphisms of cytochrome P450cl7alpha (CYP17) and progesterone receptor genes (PROGINS) in the assessment of endometriosis risk.	CYP17A1 PGR	3.66e-05	2	211	2	17484509
Pubmed	Specific Binding to Differentially Expressed Human Carcinoembryonic Antigen-Related Cell Adhesion Molecules Determines the Outcome of Neisseria gonorrhoeae Infections along the Female Reproductive Tract.	CEACAM5 CEACAM1	3.66e-05	2	211	2	29760215
Pubmed	A genome-wide association study identifies common variants influencing serum uric acid concentrations in a Chinese population.	ABCG2 SLC2A9	3.66e-05	2	211	2	24513273
Pubmed	Evolutionary conservation of centriole rotational asymmetry in the human centrosome.	C2CD3 LRRCC1	3.66e-05	2	211	2	35319462
Pubmed	AHNAK1 and AHNAK2 are costameric proteins: AHNAK1 affects transverse skeletal muscle fiber stiffness.	AHNAK AHNAK2	3.66e-05	2	211	2	20833135
Pubmed	Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells.	PGR ABCG2	3.66e-05	2	211	2	18042733
Pubmed	Genome-wide association study identifies two novel loci containing FLNB and SBF2 genes underlying stature variation.	FLNB SBF2	3.66e-05	2	211	2	19039035
Pubmed	Associations of the uric acid related genetic variants in SLC2A9 and ABCG2 loci with coronary heart disease risk.	ABCG2 SLC2A9	3.66e-05	2	211	2	25634581
Pubmed	Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1.	CEACAM5 CEACAM1	3.66e-05	2	211	2	15905509
Pubmed	Shear stress control of vascular leaks and atheromas through Tie2 activation by VE-PTP sequestration.	PTPRB TEK	3.66e-05	2	211	2	36740996
Pubmed	Nuclear factor 1 synergizes with progesterone receptor on the mouse mammary tumor virus promoter wrapped around a histone H3/H4 tetramer by facilitating access to the central hormone-responsive elements.	PGR NF1	3.66e-05	2	211	2	19940123
Pubmed	Immunohistochemical study of NG2 chondroitin sulfate proteoglycan expression in the small and large intestines.	VCAN CSPG4	3.66e-05	2	211	2	16625365
Pubmed	Carcinoembryonic antigen (CEA)-related cell adhesion molecules are co-expressed in the human lung and their expression can be modulated in bronchial epithelial cells by non-typable Haemophilus influenzae, Moraxella catarrhalis, TLR3, and type I and II interferons.	CEACAM5 CEACAM6	3.66e-05	2	211	2	23941132
Pubmed	Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan.	VCAN CSPG4	3.66e-05	2	211	2	15609081
Pubmed	The association between genetic polymorphisms in ABCG2 and SLC2A9 and urate: an updated systematic review and meta-analysis.	ABCG2 SLC2A9	3.66e-05	2	211	2	33087043
Pubmed	Human ABC transporters ABCG2 (BCRP) and ABCG4.	ABCG4 ABCG2	3.66e-05	2	211	2	18668433
Pubmed	Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers.	CEACAM5 CEACAM6	3.66e-05	2	211	2	17201906
Pubmed	Differential recognition of members of the carcinoembryonic antigen family by Afa/Dr adhesins of diffusely adhering Escherichia coli (Afa/Dr DAEC).	CEACAM5 CEACAM6	3.66e-05	2	211	2	15130118
Pubmed	Expression of complementary DNA and genomic clones for carcinoembryonic antigen and nonspecific cross-reacting antigen in Chinese hamster ovary and mouse fibroblast cells and characterization of the membrane-expressed products.	CEACAM5 CEACAM6	3.66e-05	2	211	2	2317824
Pubmed	Protein expression of carcinoembryonic antigen cell adhesion molecules in benign and malignant melanocytic skin lesions.	CEACAM5 CEACAM1	3.66e-05	2	211	2	19461083
Pubmed	Carcinoembryonic antigen family: characterization of cDNAs coding for NCA and CEA and suggestion of nonrandom sequence variation in their conserved loop-domains.	CEACAM5 CEACAM6	3.66e-05	2	211	2	3220478
Pubmed	Genetic analysis of ABCG2 and SLC2A9 gene polymorphisms in gouty arthritis in a Korean population.	ABCG2 SLC2A9	3.66e-05	2	211	2	26552468
Pubmed	Haplotypic diversity in human CEACAM genes: effects on susceptibility to meningococcal disease.	CEACAM6 CEACAM1	3.66e-05	2	211	2	17960155
Pubmed	T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interaction.	CEACAM6 CEACAM1	3.66e-05	2	211	2	35141051
Pubmed	The AHNAKs are a class of giant propeller-like proteins that associate with calcium channel proteins of cardiomyocytes and other cells.	AHNAK AHNAK2	3.66e-05	2	211	2	15007166
Pubmed	FBLN-4 and BCRP genes as two prognostic markers are downregulated in breast cancer tissue.	FBLN1 ABCG2	3.66e-05	2	211	2	28282800
Pubmed	Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg.	F8 RAG2	3.66e-05	2	211	2	25833958
Pubmed	CD66 identifies the biliary glycoprotein (BGP) adhesion molecule: cloning, expression, and adhesion functions of the BGPc splice variant.	CEACAM6 CEACAM1	3.66e-05	2	211	2	8018919
Pubmed	Mitochondrial morphogenesis, dendrite development, and synapse formation in cerebellum require both Bcl-w and the glutamate receptor delta2.	BCL2L2 GRID2	3.66e-05	2	211	2	18551174
Pubmed	Targeting the vascular-specific phosphatase PTPRB protects against retinal ganglion cell loss in a pre-clinical model of glaucoma.	PTPRB TEK	3.66e-05	2	211	2	31621585
Pubmed	An update on the genetic architecture of hyperuricemia and gout.	ABCG2 SLC2A9	3.66e-05	2	211	2	25889045
GeneFamily	Fibronectin type III domain containing	EPHB2 IGFN1 PTPRB LRFN5 ROBO3 TEK ATF7IP OSMR EPHA10 EPHA8	5.42e-07	160	142	10	555
GeneFamily	Adenosine receptors\|V-set domain containing	CEACAM5 CEACAM6 CADM2 CEACAM1 PIGR NECTIN1 VCAN NCAN	4.43e-05	163	142	8	590
GeneFamily	Fibronectin type III domain containing\|Sterile alpha motif domain containing\|EPH receptors	EPHB2 EPHA10 EPHA8	1.62e-04	14	142	3	1095
GeneFamily	PDZ domain containing	PARD6B AHNAK SHANK1 PPP1R9A HTRA3 SDCBP2 AHNAK2	1.99e-04	152	142	7	1220
GeneFamily	Blood group antigens\|CD molecules\|I-set domain containing\|Immunoglobulin like domain containing	IGFN1 CEACAM5 CADM2 IGSF10 HMCN2 LRFN5 ROBO3	2.83e-04	161	142	7	593
GeneFamily	ADAM metallopeptidase domain containing\|CD molecules	CEACAM5 CD109 CEACAM6 CEACAM1 NRP1 NECTIN1 ABCG2 LAMP2 CDCP1 TEK ENG	2.85e-04	394	142	11	471
GeneFamily	Hyalectan proteoglycans\|V-set domain containing\|Sushi domain containing\|C-type lectin domain containing	VCAN NCAN	3.64e-04	4	142	2	574
GeneFamily	Blood group antigens\|CD molecules\|ATP binding cassette subfamily G	ABCG4 ABCG2	6.03e-04	5	142	2	811
GeneFamily	Acid sensing ion channel subunits	ASIC2 ASIC4	6.03e-04	5	142	2	290
GeneFamily	Sterile alpha motif domain containing	EPHB2 SHANK1 PPP1R9A EPHA10 EPHA8	6.47e-04	88	142	5	760
GeneFamily	Immunoglobulin like domain containing	CEACAM5 CEACAM6 CEACAM1 HMCN2 NECTIN1 ROBO3 TEK	8.38e-04	193	142	7	594
GeneFamily	CD molecules\|V-set domain containing\|Immunoglobulin like domain containing\|Carcinoembryonic antigen related cell adhesion molecule family	CEACAM5 CEACAM6 CEACAM1	8.51e-04	24	142	3	906
GeneFamily	WD repeat domain containing	DMXL1 WDR20 WDR90 DMXL2 PPWD1 WDHD1 WDFY3 LRBA	1.10e-03	262	142	8	362
GeneFamily	Blood group antigens\|CD molecules\|Proteoglycans	CSPG4 AGRN	1.25e-03	7	142	2	570
GeneFamily	Fibulins	FBLN1 HMCN2	1.66e-03	8	142	2	556
GeneFamily	WD repeat domain containing\|BEACH domain containing	WDFY3 LRBA	2.13e-03	9	142	2	1230
GeneFamily	Hyalectan proteoglycans\|V-set domain containing\|Sushi domain containing\|C-type lectin domain containing	PKD1 VCAN NCAN	4.06e-03	41	142	3	1298
GeneFamily	DNA helicases	NCL RUVBL1	7.71e-03	17	142	2	1167
Coexpression	NABA_CORE_MATRISOME	IGSF10 FBLN1 HMCN2 COL21A1 ZPLD1 ECM2 COL5A3 TECTA LGI3 VCAN NCAN AGRN	2.48e-06	275	210	12	M5884
Coexpression	GSE5503_MLN_DC_VS_PLN_DC_ACTIVATED_ALLOGENIC_TCELL_DN	MAML1 WNK1 PGR PLEKHA7 WDHD1 ATF7IP LGI3 GRAMD2B HELZ2 UBA6	5.27e-06	200	210	10	M291
Coexpression	NABA_MATRISOME	TMPRSS15 CD109 IGSF10 FREM2 FBLN1 HMCN2 MUCL1 COL21A1 ZPLD1 ECM2 ANXA7 COL5A3 HTRA3 MUC5B TECTA TIMP1 LGI3 VCAN NCAN CSPG4 AGRN MUC6 SERPIND1	9.10e-06	1026	210	23	M5889
Coexpression	NABA_CORE_MATRISOME	IGSF10 FBLN1 HMCN2 ZPLD1 ECM2 COL5A3 TECTA LGI3 VCAN NCAN AGRN	1.25e-05	270	210	11	MM17057
Coexpression	HIRSCH_CELLULAR_TRANSFORMATION_SIGNATURE_UP	AGFG1 ROBO3 ANXA7 CDCP1 CREM APPL2 TIMP1 UBA6 OSMR PROS1	2.76e-05	242	210	10	M2123
Coexpression	GSE411_WT_VS_SOCS3_KO_MACROPHAGE_IL6_STIM_400MIN_UP	NECTIN1 FNIP1 RNF138 FLNB DOCK8 B3GNT7 VPS37B SBF2 GRAMD2B	3.60e-05	200	210	9	M5994
Coexpression	GSE37301_LYMPHOID_PRIMED_MPP_VS_COMMON_LYMPHOID_PROGENITOR_UP	CYP17A1 WNK1 GGT5 PIGR USF2 PLEKHA7 HSPA4L POLA1 ZNF281	3.60e-05	200	210	9	M8853
Coexpression	GSE360_DC_VS_MAC_L_DONOVANI_DN	SREBF2 NCL TSC22D1 USF2 MGA DMXL2 TIMP1 WDFY3 MUC6	3.60e-05	200	210	9	M5176
Coexpression	JOHNSTONE_PARVB_TARGETS_3_UP	PARD6B AHNAK ABCG2 FLNB DNAH2 CDCP1 ARL4C TIMP1 LPCAT3 HELZ2 OSMR AGRN AHNAK2	5.13e-05	433	210	13	M2240
Coexpression	NABA_MATRISOME	TMPRSS15 CD109 IGSF10 FREM2 FBLN1 HMCN2 ZPLD1 ECM2 ANXA7 COL5A3 HTRA3 MUC5B TECTA TIMP1 LGI3 VCAN NCAN CSPG4 AGRN MUC6 SERPIND1	6.55e-05	1008	210	21	MM17056
Coexpression	GSE12003_4D_VS_8D_CULTURE_MIR223_KO_BM_PROGENITOR_DN	SYNJ2 AHNAK OPLAH HDHD5 ANXA7 TEX15 GRAMD2B SDCBP2	6.60e-05	168	210	8	M403
Coexpression	GSE15624_3H_VS_6H_HALOFUGINONE_TREATED_CD4_TCELL_UP	KIAA0319L MAML1 WNK1 RNF138 HDHD5 ATP8B2 TMEM108 KDM4B	7.47e-05	171	210	8	M7105
Coexpression	GSE9601_UNTREATED_VS_NFKB_INHIBITOR_TREATED_HCMV_INF_MONOCYTE_DN	NF1 AGFG1 MGA XRCC5 LPCAT3 SBF2 SERTAD4 LRRCC1	8.44e-05	174	210	8	M6881
Coexpression	SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_DN	MAP2 CD109 CEACAM6 FREM2 PIGR SERTAD4 PROS1 AHNAK2	8.78e-05	175	210	8	M6750
CoexpressionAtlas	Stem Cells, SC.LTSL.BM, IgM- CD24- CD117+ IL7R- CD150+ CD48- AA4.1+ CD43+, Bone marrow, avg-2	CEACAM1 NEDD4 ABCG2 ROBO3 DMXL2 POLA1 PPP1R9A CDCP1 TEK ADGRG7 ARHGEF40 DOCK7 CKAP2L PRKCE WDFY3 ENG	3.94e-06	422	206	16	GSM399442_500
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Ascending_Vasa_Recta_Endothelial_Cell_prolif\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ADGRB3 F8 CEACAM1 NEDD4 PTPRB MUCL1 ST8SIA6 CACNA2D1 POLA1 TEK ENG EPHA8	4.05e-11	172	211	12	c056d44e2e130ceccadfcdceb192a7f095d779c8
ToppCell	COVID-19-kidney-Technical/muscle_(EC)\|kidney / Disease (COVID-19 only), tissue and cell type	ADGRB3 CADM2 PTPRB ST8SIA6 PCDH11Y GRID2 TEX15 GABBR2 ADGRG7 TMEM132D	1.31e-09	139	211	10	64c35411bbe67acb5010dadc4b0b1be0f8b17737
ToppCell	Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_1_cell-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	ADGRB3 RYR2 NRP1 SYNJ2 LRFN5 FAT3 TIMP1 VCAN TMEM108 OSMR ENG	2.05e-09	191	211	11	08720998aa55131d7377c4c67c4c935865bd7d79
ToppCell	Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_1_cell\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	ADGRB3 ABCA8 RYR2 NRP1 FBLN1 COL21A1 LRFN5 CACNA2D1 FAT3 VCAN TMEM108	2.42e-09	194	211	11	011e14d9ed1393275f892060e7708ffadcd0767f
ToppCell	Macroglial-Polydendrocytes\|Macroglial / cells hierarchy compared to all cells using T-Statistic	MAP2 ASIC2 RNF150 LRFN5 ASIC4 PCDH11Y GRID2 TEK TMEM132D VCAN CSPG4	3.32e-09	200	211	11	961858738ce35db8760c8c2e136f8369bc444ccf
ToppCell	Macroglial-Polydendrocytes-PDGFRA-\|Macroglial / cells hierarchy compared to all cells using T-Statistic	MAP2 ASIC2 RNF150 LRFN5 ASIC4 PCDH11Y GRID2 TEK TMEM132D VCAN CSPG4	3.32e-09	200	211	11	f17b5a54e8f9eba9dcd0808ba4e8d275ac41bce2
ToppCell	Macroglial-Polydendrocytes-PDGFRA--\|Macroglial / cells hierarchy compared to all cells using T-Statistic	MAP2 ASIC2 RNF150 LRFN5 ASIC4 PCDH11Y GRID2 TEK TMEM132D VCAN CSPG4	3.32e-09	200	211	11	cc3409518f8b436ea92deb955e81114b3f410ff7
ToppCell	Macroglial-Polydendrocytes-PDGFRA\|Macroglial / cells hierarchy compared to all cells using T-Statistic	MAP2 ASIC2 RNF150 LRFN5 ASIC4 PCDH11Y GRID2 TEK TMEM132D VCAN CSPG4	3.32e-09	200	211	11	c24a3099e3d96d8b72f6d05286bb355d661a0377
ToppCell	Macroglial-Polydendrocytes-PDGFRA---\|Macroglial / cells hierarchy compared to all cells using T-Statistic	MAP2 ASIC2 RNF150 LRFN5 ASIC4 PCDH11Y GRID2 TEK TMEM132D VCAN CSPG4	3.32e-09	200	211	11	4fc3de4bff7ed2bf40b38462c4b4e9b87af6a4ca
ToppCell	Macroglial-Polydendrocytes-PDGFRA----L1-6\|Macroglial / cells hierarchy compared to all cells using T-Statistic	MAP2 ASIC2 RNF150 LRFN5 ASIC4 PCDH11Y GRID2 TEK TMEM132D VCAN CSPG4	3.32e-09	200	211	11	310cd53db1c137f6af74e6ae682221d7ac27310c
ToppCell	droplet-Heart-nan-3m\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZBTB20 RYR2 NEDD4 IGSF10 FBLN1 PSME4 AHNAK ECM2 HTRA3 ATF7IP	1.28e-08	176	211	10	749b47eac5436fa34e0d243ffbc6f1897f4e431e
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ADGRB3 ABCA8 RYR2 NRP1 IGSF10 FBLN1 COL21A1 LRFN5 FAT3 TMEM108	1.67e-08	181	211	10	9ede19228ba5c0668a9c06c915510b95585216ef
ToppCell	Adult-Mesenchymal-matrix_fibroblast_1_cell-D175\|Adult / Lineage, Cell type, age group and donor	IGFN1 ADGRB3 RYR2 NRP1 RNF150 FBLN1 COL21A1 LRFN5 CACNA2D1 TMEM108	2.28e-08	187	211	10	e15d2967aac248da3517bc2c7d1beaa1d5a0aa7f
ToppCell	Mesenchymal-matrix_fibroblast_1_cell\|World / Lineage, Cell type, age group and donor	ADGRB3 ABCA8 RYR2 NRP1 FBLN1 COL21A1 LRFN5 CACNA2D1 FAT3 TMEM108	3.07e-08	193	211	10	acad568621ed677031797b8c2e34dafea798d681
ToppCell	Children_(3_yrs)-Mesenchymal\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ADGRB3 ABCA8 RYR2 IGSF10 FBLN1 COL21A1 LRFN5 CACNA2D1 FAT3 COL5A3	3.56e-08	196	211	10	bc94909f9b2dc08a59eef1914148b69720569c8f
ToppCell	Fetal_29-31_weeks-Mesenchymal\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	ADGRB3 ABCA8 RYR2 NRP1 FBLN1 COL21A1 LRFN5 CACNA2D1 FAT3 VCAN	3.91e-08	198	211	10	21cf4d81386761d09d0f6829c01c198e5524176d
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	MAP2 CD109 ADGRB3 CEACAM1 NEDD4 PTPRB ST8SIA6 SYNJ2 TEK ENG	3.91e-08	198	211	10	b027a141ab531d0f5d6a26811a53427e7b0771dd
ToppCell	Bronchial-NucSeq-Stromal-Fibroblastic-Fibro_alveolar\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	ADGRB3 ACTN2 ABCA8 RYR2 NRP1 FBLN1 COL21A1 LRFN5 FAT3 TMEM108	4.30e-08	200	211	10	e8462395fee0a532d1e7ec7f1795f28c42af6541
ToppCell	3'-Pediatric_IBD-SmallIntestine-Epithelial-goblet-BEST2+_Goblet_cell\|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CEACAM5 BEST2 CEACAM6 CEACAM1 IGHV1-69D FCGBP PIGR B3GNT7 EPHA10	1.97e-07	179	211	9	c833ded1f9e87be2ba2037820d92a389560b711c
ToppCell	Control-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ACTN2 ABCA8 RYR2 IGSF10 FBLN1 COL21A1 ECM2 FAT3 TMEM108	2.06e-07	180	211	9	08ae0f5d95c45feba68ad99788f7af7ff4c979af
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen+matrisome-high_fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ABCA8 CADM2 NRP1 GGT5 FBLN1 LRFN5 ECM2 FAT3 COL5A3	2.27e-07	182	211	9	b7d532feb73167e05475855061b35a209583f44c
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen+matrisome-high_fibroblast-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ABCA8 CADM2 NRP1 GGT5 FBLN1 LRFN5 ECM2 FAT3 COL5A3	2.27e-07	182	211	9	af65f0fc3f9e5d9ce69ee5faaf5b6cb7f8412e0c
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TMPRSS15 IGFN1 CADM2 RYR2 FREM2 ANK1 FAT3 MUC5B EPHA10	2.49e-07	184	211	9	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TMPRSS15 IGFN1 CADM2 RYR2 FREM2 ANK1 FAT3 MUC5B EPHA10	2.49e-07	184	211	9	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TMPRSS15 IGFN1 CADM2 RYR2 FREM2 ANK1 FAT3 MUC5B EPHA10	2.49e-07	184	211	9	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	droplet-Bladder-nan-24m-Endothelial-nan\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAP2 F8 PTPRB ABCG2 WSCD1 DNAH2 TEK CSPG4 ENG	2.60e-07	185	211	9	90caab8d9361a541c5d5121c97c3f1cdffeeae4a
ToppCell	facs-Brain_Non-Myeloid-Cerebellum_-18m-Endothelial-Endothelial_cell\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CEACAM1 NRP1 TSC22D1 PTPRB AHNAK ABCG2 TEK TLNRD1 ENG	2.73e-07	186	211	9	ba6ba75218efc26371cea24ddbb0e9b3e3f421ac
ToppCell	facs-Brain_Non-Myeloid-Cerebellum_-18m-Endothelial\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CEACAM1 NRP1 TSC22D1 PTPRB AHNAK ABCG2 TEK TLNRD1 ENG	2.73e-07	186	211	9	65e25a9dcef5fc71510aaf170e220deef5b2feb2
ToppCell	facs-Brain_Non-Myeloid-Cerebellum_-18m-Endothelial-endothelial_cell\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CEACAM1 NRP1 TSC22D1 PTPRB AHNAK ABCG2 TEK TLNRD1 ENG	2.73e-07	186	211	9	e4f1259725160719e5fd13d76e5a707efed70013
ToppCell	E18.5-Endothelial-Endothelial_blood-vessel-Microvascular_EC-CAP1\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CD109 MAML1 NRP1 PTPRB WSCD1 FLNB ECM2 CCNJ TEK	2.85e-07	187	211	9	3699d5e71d779da922920aa3160895db187bf81b
ToppCell	E18.5-Endothelial-Endothelial_blood-vessel-Microvascular_EC-CAP1-CAP1_mature\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CD109 MAML1 NRP1 PTPRB WSCD1 FLNB ECM2 CCNJ TEK	2.85e-07	187	211	9	033ba52c0c2f9978784947098fa697368ae44834
ToppCell	Primary_Visual_cortex_(V1C)-Non-neuronal-Macroglial-Oligo-OPC-OPC_L1-6_MYT1\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ZBTB20 ASIC4 WSCD1 COL5A3 GRID2 B3GNT7 TEK VCAN CSPG4	2.85e-07	187	211	9	5b7a1edee602e55d3400dc17dbb6b8aaa26defc0
ToppCell	LV-10._Endothelium_II\|World / Chamber and Cluster_Paper	F8 NEDD4 PTPRB ST8SIA6 FLNB PCDH11Y TECTA TEK ENG	2.85e-07	187	211	9	7876dcb4800c2e54874df3d933efb79307a64a97
ToppCell	Primary_Visual_cortex_(V1C)-Non-neuronal-Macroglial-Oligo-OPC\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ZBTB20 ASIC4 WSCD1 COL5A3 GRID2 B3GNT7 TEK VCAN CSPG4	2.85e-07	187	211	9	daff7ccd3f1924cf2b34d3aca3eccde245aaf371
ToppCell	Control-Fibroblasts-Alveolar_FB\|Control / group, cell type (main and fine annotations)	ADGRB3 ACTN2 ABCA8 RYR2 FBLN1 COL21A1 FAT3 GRID2 TMEM108	2.85e-07	187	211	9	92d468dde81125d51daf7abd4703741abe1ab91c
ToppCell	Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_1_cell-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	ADGRB3 ABCA8 PGR IGSF10 FBLN1 COL21A1 CACNA2D1 ECM2 FAT3	3.12e-07	189	211	9	203c80030df08ae112f9ae4043709f455d87ce89
ToppCell	RA-10._Endothelium_II\|World / Chamber and Cluster_Paper	F8 PTPRB ST8SIA6 FLNB TEK VCAN TMEM108 OSMR ENG	3.12e-07	189	211	9	75c248b9de5e2fb7a0baa8cdbab516e575cc4394
ToppCell	Severe_COVID-19-Epithelial-undefined_Epi\|Severe_COVID-19 / Disease group,lineage and cell class （2021.01.30）	CEACAM5 CEACAM6 PARD6B TSC22D1 PIGR MUC5B GRAMD2B OSMR SDCBP2	3.12e-07	189	211	9	8cbd35320c7e7ff013ef0c0f13f8d875db1c53cd
ToppCell	Control-Fibroblasts\|Control / group, cell type (main and fine annotations)	ADGRB3 ABCA8 RYR2 FBLN1 COL21A1 LRFN5 CACNA2D1 FAT3 VCAN	3.26e-07	190	211	9	3a42a9b98d954685d38a741f44545898d0e3e9ce
ToppCell	droplet-Heart-nan-3m-Mesenchymal\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZBTB20 RYR2 NEDD4 IGSF10 FBLN1 COL5A3 HTRA3 ARHGEF40 VCAN	3.26e-07	190	211	9	96a92212ea3fb35fa3d0da495e504edc61c71c23
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-3m-Endothelial-Endothelial_cell\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CEACAM1 NRP1 TSC22D1 PTPRB AHNAK ABCG2 TEK OSMR ENG	3.56e-07	192	211	9	9d53b42cdb537b30233cdfdc08052c8b13a1113f
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-3m-Endothelial-endothelial_cell\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CEACAM1 NRP1 TSC22D1 PTPRB AHNAK ABCG2 TEK OSMR ENG	3.56e-07	192	211	9	042391162df2e3d0027688dd14163c4c6821afe0
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-3m-Endothelial\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CEACAM1 NRP1 TSC22D1 PTPRB AHNAK ABCG2 TEK OSMR ENG	3.56e-07	192	211	9	71b0bfee0461ff64cef35881db3959c517e9731b
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-Mono-Mono_hypoxia-E\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	NRP1 SIMC1 AGFG1 DMXL2 CDCP1 TLNRD1 TIMP1 VCAN ENG	3.72e-07	193	211	9	d9bb77214bb92e8392cf74e3bfdf177a96fd71ea
ToppCell	RV-10._Endothelium_II\|World / Chamber and Cluster_Paper	F8 NEDD4 PTPRB ST8SIA6 FLNB TEK TMEM108 OSMR ENG	3.72e-07	193	211	9	2531266bc57339d4e2b22a88817008e32b8c1598
ToppCell	RV-10._Endothelium_II\|RV / Chamber and Cluster_Paper	F8 NEDD4 PTPRB ST8SIA6 FLNB TEK TMEM108 OSMR ENG	3.72e-07	193	211	9	01c2df9206f1527c578e808978e58196c35e72f5
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ADGRB3 ABCA8 IGSF10 FBLN1 LRFN5 FAT3 GRID2 TMEM108 OSMR	3.89e-07	194	211	9	89b706af2b25991fc2707eb24f49ba6ff3ae01f7
ToppCell	LV-10._Endothelium_II\|LV / Chamber and Cluster_Paper	PTPRB ST8SIA6 FLNB PCDH11Y TECTA TEK TMEM108 OSMR ENG	3.89e-07	194	211	9	b6cc849fa08599bff9839ef382d190cc964e273e
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ADGRB3 ABCA8 IGSF10 FBLN1 COL21A1 LRFN5 FAT3 GRID2 TMEM108	3.89e-07	194	211	9	60622bd2f75bfe4c37f721cb12f03dab33f2f58d
ToppCell	facs-Diaphragm-Limb_Muscle-3m-Mesenchymal\|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZBTB20 RPN2 NEDD4 CSDE1 AHNAK HTRA3 LAMP2 OSMR PROS1	4.06e-07	195	211	9	4d63e0dca30ae57960459d2fbcba09122273e37b
ToppCell	facs-Diaphragm-Limb_Muscle-3m-Mesenchymal-nan\|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZBTB20 RPN2 NEDD4 CSDE1 AHNAK HTRA3 LAMP2 OSMR PROS1	4.06e-07	195	211	9	661af601a3561fe3aacf2444ad7b8927fa88b48a
ToppCell	Adult-Mesenchymal-matrix_fibroblast_1_cell-D122\|Adult / Lineage, Cell type, age group and donor	ADGRB3 ABCA8 CADM2 RYR2 IGSF10 COL21A1 ECM2 FAT3 TMEM108	4.06e-07	195	211	9	aa0add081881d349099d12efca5cdee098038d4e
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	CD109 ADGRB3 CEACAM1 NEDD4 PTPRB ST8SIA6 SYNJ2 TEK ENG	4.24e-07	196	211	9	b8f89a50114932c08fc5daac4b549adfe9df8e66
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	ADGRB3 ABCA8 FBLN1 COL21A1 CACNA2D1 FAT3 VCAN SBF2 TMEM108	4.24e-07	196	211	9	1450cb69c5bf469e97c03bf1890f6f7c54165b8a
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	CD109 ADGRB3 CEACAM1 NEDD4 PTPRB ST8SIA6 SYNJ2 TEK ENG	4.24e-07	196	211	9	145fcf73deba9638b391a1af6c39fa205dc9829f
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-Mono-Mono_hypoxia\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	CD109 NRP1 FLNB DMXL2 CDCP1 TLNRD1 TIMP1 VCAN ENG	4.24e-07	196	211	9	a44a648bf209ce037bfc7b3adfcb220aab60728c
ToppCell	10x_3'_v2v3-Neoplastic-Differentiated-like-MES-like-MES-like_hypoxia_independent-F\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ZBTB20 IGSF10 FREM2 PKD1 ASIC4 ADGRG7 TIMP1 P2RX6 OSMR	4.24e-07	196	211	9	b8b9801181d7604871b48aebacb295d0a57a5eaf
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Endothelial\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	CD109 ADGRB3 CEACAM1 NEDD4 PTPRB ST8SIA6 SYNJ2 TEK ENG	4.24e-07	196	211	9	d0ff1082898d2db47c88d2678466514e9e9193d3
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature3_(17)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	ADGRB3 ABCA8 IGSF10 FBLN1 COL21A1 FAT3 VCAN SBF2 TMEM108	4.42e-07	197	211	9	31a1852911bda38543916585fda34255fd62a134
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	ADGRB3 ABCA8 IGSF10 COL21A1 LRFN5 FAT3 VCAN SBF2 TMEM108	4.42e-07	197	211	9	0034bae02ee7fcfea520d453ca3c842ab6963b12
ToppCell	facs-Trachea-nan-3m-Mesenchymal-fibroblast\|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZBTB20 NEDD4 IGSF10 FBLN1 ECM2 COL5A3 HTRA3 VCAN PROS1	4.61e-07	198	211	9	0dc7d59a07428a7b7e8bdc81f0e2417dd4ce3cf2
ToppCell	COVID-19-lung-Fibroblast\|COVID-19 / Disease (COVID-19 only), tissue and cell type	ADGRB3 RYR2 FBLN1 COL21A1 LRFN5 FAT3 TIMP1 VCAN TMEM108	4.61e-07	198	211	9	3ec01a55ade5e1627258cc3cfebb2c3207a4cb43
ToppCell	LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	ACTN2 ABCA8 RYR2 IGSF10 FBLN1 COL21A1 TIMP1 VCAN OSMR	4.81e-07	199	211	9	a7dd94b172c973a131a6792f8ccd9bfe44d984ac
ToppCell	Brain_organoid-organoid_Tanaka_cellReport-2m-Neuroepithelial\|2m / Sample Type, Dataset, Time_group, and Cell type.	IGFN1 GGT5 FBLN1 COL21A1 COL5A3 HTRA3 TIMP1 VCAN ENG	5.02e-07	200	211	9	3da9441c0f1e242f0d195de47ecd4c24dfdca232
ToppCell	Brain_organoid-organoid_Tanaka_cellReport-2m-Neuroepithelial-Proteoglycan-expressing_cell\|2m / Sample Type, Dataset, Time_group, and Cell type.	IGFN1 GGT5 FBLN1 COL21A1 COL5A3 HTRA3 TIMP1 VCAN ENG	5.02e-07	200	211	9	eed2bafddcd041ef5fcc4d1d31edb8be4d83ce01
ToppCell	Parenchymal-NucSeq-Stromal\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	ADGRB3 ABCA8 RYR2 NRP1 FBLN1 COL21A1 LRFN5 FAT3 VCAN	5.02e-07	200	211	9	cf433f9b43d7db07acaf70e060f8f77c974e72f3
ToppCell	LPS_only-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_only / Treatment groups by lineage, cell group, cell type	ACTN2 ABCA8 RYR2 NRP1 FBLN1 COL21A1 TIMP1 VCAN OSMR	5.02e-07	200	211	9	a7ef7022b8efcaedb7319b0b43d8c4e99d788fe2
ToppCell	Parenchymal-NucSeq-Stromal-Fibroblastic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	ADGRB3 ABCA8 RYR2 NRP1 FBLN1 COL21A1 LRFN5 FAT3 VCAN	5.02e-07	200	211	9	311fab076f2ceb258e3970eb21e39344b894042a
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Ascending_Vasa_Recta_Endothelial_Cell_prolif\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ADGRB3 CEACAM1 PTPRB ST8SIA6 CACNA2D1 POLA1 TEK ENG	7.81e-07	155	211	8	babcb9e548f04ace8157d506d27c5941c692c491
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell-Peritubular_Capilary_Endothelial_Cell__prolif\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	CD109 ADGRB3 CEACAM1 PTPRB HTRA3 TEK HELZ2 ENG	7.81e-07	155	211	8	59035d792c26d870a8b097939e97fa47859ba68c
ToppCell	COVID-19-kidney-Epithelial_(EC)\|kidney / Disease (COVID-19 only), tissue and cell type	CD109 ADGRB3 F8 CEACAM1 PTPRB TEK TMEM132D ENG	9.93e-07	160	211	8	0d4880f85565d8c540c94a8f8109147b3029279a
ToppCell	TCGA-Brain-Primary_Tumor-Low_Grade_Glioma-Astrocytoma\|TCGA-Brain / Sample_Type by Project: Shred V9	KIAA0319L CSDE1 AGO3 AHNAK USF2 MGA DOCK8 DOCK7	1.09e-06	162	211	8	810881210e015c788814e4fe8d7a24c929cf2621
ToppCell	Adult-Immune-enucleated_erythrocyte-D231\|Adult / Lineage, Cell type, age group and donor	ACTN2 NECTIN1 MED10 ANK1 HSPA4L ODC1 GABBR2 PROS1	2.12e-06	177	211	8	15ee303fb6caea1fd645c3b777666196ce500a1c
ToppCell	BAL-Severe-Epithelial-Epithelial-undefined_Epi\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CEACAM5 CEACAM6 PARD6B PIGR MUC5B GRAMD2B OSMR SDCBP2	2.21e-06	178	211	8	49a2271718637522f74334068d252963ee13b1ce
ToppCell	3'-Distal_airway-Mesenchymal-Fibroblastic-fibroblastic_type_2-Peribronchial_fibroblasts\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGFN1 ADGRB3 ACTN2 PGR FBLN1 CACNA2D1 ECM2 FAT3	2.21e-06	178	211	8	09475e522dc1b8cf9ff1c25de5d1e3082b162948
ToppCell	3'-Distal_airway-Mesenchymal-Fibroblastic-fibroblastic_type_2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGFN1 ADGRB3 ACTN2 PGR FBLN1 CACNA2D1 ECM2 FAT3	2.21e-06	178	211	8	000d25f3f13cc76cf39c46c312c6fafc2ea4f368
ToppCell	Club_cells-SSc-ILD_01\|World / lung cells shred on cell class, cell subclass, sample id	CEACAM6 GGT5 FCGBP MUCL1 PIGR MUC5B ARL4C GRAMD2B	2.21e-06	178	211	8	be64d4be23fb96a4cdd7980c58880fdfe817747f
ToppCell	BAL-Severe-Epithelial-Epithelial-undefined_Epi-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	CEACAM5 CEACAM6 PARD6B PIGR MUC5B GRAMD2B OSMR SDCBP2	2.21e-06	178	211	8	9a3ef66814dfca7b37024e7f79e86ea8c72ae10f
ToppCell	BAL-Severe-Epithelial-Epithelial-undefined_Epi-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CEACAM5 CEACAM6 PARD6B PIGR MUC5B GRAMD2B OSMR SDCBP2	2.21e-06	178	211	8	b413a634283550fa224db7d0d05956e3f64694a1
ToppCell	3'-Distal_airway-Mesenchymal-Fibroblastic-fibroblastic_type_2-Peribronchial_fibroblasts-Peribronchial_fibroblasts_L.2.1.3.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGFN1 ADGRB3 ACTN2 PGR FBLN1 CACNA2D1 ECM2 FAT3	2.21e-06	178	211	8	35de8f791b0e78a6caf52ff095f05e204a59e828
ToppCell	BAL-Severe-Epithelial-Epithelial-undefined_Epi\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	CEACAM5 CEACAM6 PARD6B PIGR MUC5B GRAMD2B OSMR SDCBP2	2.21e-06	178	211	8	19b5432aa1d7f616d58a106543c18cf2d7ca840c
ToppCell	facs-Lung-3m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l17\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	FBLN1 ECM2 COL5A3 HTRA3 ARHGEF40 TIMP1 VCAN SERTAD4	2.40e-06	180	211	8	39ae8586efd91536e9ac6408d26de7e6d6237c41
ToppCell	Control-Stromal_mesenchymal-Matrix_Fibroblast\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ACTN2 ABCA8 IGSF10 FBLN1 COL21A1 ECM2 FAT3 TMEM108	2.40e-06	180	211	8	9b1de1b4711adbf9a423f4d2d08f3f4c78f1f8f4
ToppCell	Control-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ACTN2 ABCA8 IGSF10 FBLN1 COL21A1 ECM2 FAT3 TMEM108	2.50e-06	181	211	8	9e7d0f1afb8d9bc5a209ddb5314df3a25a0274d9
ToppCell	facs-Pancreas-Exocrine-18m-Mesenchymal\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GGT5 IGSF10 FBLN1 ECM2 COL5A3 HTRA3 TIMP1 VCAN	2.50e-06	181	211	8	269b39ac65790061d54eab47a8eeb024403f0348
ToppCell	facs-Pancreas-Exocrine-18m-Mesenchymal-pancreatic_stellate_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GGT5 IGSF10 FBLN1 ECM2 COL5A3 HTRA3 TIMP1 VCAN	2.50e-06	181	211	8	c8395ae872aa80b3ae1ab7c53e57b3ca15aeb0e2
ToppCell	droplet-Heart-nan-24m-Endothelial\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CEACAM1 NRP1 PTPRB WSCD1 FLNB TEK TMEM108 ENG	2.50e-06	181	211	8	859c40889ede2cbf374c4d2efbb72dc3bc6441f5
ToppCell	facs-Pancreas-Exocrine-18m-Mesenchymal-pancreatic_stellate_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GGT5 IGSF10 FBLN1 ECM2 COL5A3 HTRA3 TIMP1 VCAN	2.50e-06	181	211	8	cd4f744b6b64ba6c22ec07afd1d3058a2546909d
ToppCell	Pericytes-SSc-ILD_01\|World / lung cells shred on cell class, cell subclass, sample id	ACTN2 HMCN2 LRFN5 FLNB ANK1 ECM2 COL5A3 CSPG4	2.50e-06	181	211	8	35c470988a93381eefa300831aabb813fa1b90bd
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-24m-Endothelial-Endothelial_cell\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TSC22D1 PTPRB AHNAK ABCG2 POLK FLNB TEK ENG	2.60e-06	182	211	8	ccc313ecc0bfd8e2c6bb83a565b427b2310485ec
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-24m-Endothelial-endothelial_cell\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TSC22D1 PTPRB AHNAK ABCG2 POLK FLNB TEK ENG	2.60e-06	182	211	8	b9f758961fb4a586ae86fa0b25edb8ce4616d644
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-24m-Endothelial\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TSC22D1 PTPRB AHNAK ABCG2 POLK FLNB TEK ENG	2.60e-06	182	211	8	e6a734fb29105093d4cbfc3d0619a825b66da034
ToppCell	facs-Brain_Non-Myeloid-Cerebellum_-18m\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CEACAM1 TSC22D1 PTPRB AHNAK ABCG2 ANXA7 TLNRD1 ENG	2.60e-06	182	211	8	ef65b095f4240d61cfd4a59aec19d72d324dba1d
ToppCell	facs-Brain_Non-Myeloid-Cerebellum_\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CEACAM1 TSC22D1 PTPRB AHNAK ABCG2 ANXA7 TLNRD1 ENG	2.60e-06	182	211	8	97a805783a1f2b055c21307db250e3688674eff3
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_hypoxia/MES-E\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	CD109 NRP1 FLNB DMXL2 CDCP1 VCAN UBA6 ENG	2.82e-06	184	211	8	e343dd7777a29048e3f12a939f7f782b8b7b4fea
ToppCell	facs-Brain_Non-Myeloid-Cortex_-18m-Endothelial-endothelial_cell\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CEACAM1 NRP1 TSC22D1 PTPRB AHNAK ABCG2 TEK ENG	2.94e-06	185	211	8	7f46ea82a663181957f88e4e83114aef8a78820c
ToppCell	facs-Brain_Non-Myeloid-Cortex_-18m-Endothelial\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CEACAM1 NRP1 TSC22D1 PTPRB AHNAK ABCG2 TEK ENG	2.94e-06	185	211	8	956fb0043c0c3e4e5c4d6f58ff95faf6209c380e
ToppCell	Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Oligo-OPC-OPC_L1-6_MYT1\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ZBTB20 ASIC4 WSCD1 B3GNT7 TEK VCAN CSPG4 GRAMD2B	2.94e-06	185	211	8	2e1766f1a972fecd670daaaf7eb2d3a404f121e7
ToppCell	Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Oligo-OPC\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ZBTB20 ASIC4 WSCD1 B3GNT7 TEK VCAN CSPG4 GRAMD2B	2.94e-06	185	211	8	7aaa8335b40927e3e8fdcede807cd521fc213a0d
ToppCell	kidney_cells-Adult_normal_reference-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ABCA8 PGR GGT5 FBLN1 MUCL1 ECM2 TIMP1 ZC3HAV1L	2.94e-06	185	211	8	e1fbec55b71f604189eb2431768fadbaa0453a83
Drug	Metoclopramide monohydrochloride [7232-21-5]; Up 200; 11.8uM; PC3; HT_HG-U133A	TMPRSS15 KIAA0319L ACTN2 WNK1 NF1 ABCG2 EXOG SHANK1 ECM2 GABBR2 PRKCE KDM4B	2.85e-07	198	207	12	3728_UP
Drug	Methionine sulfoximine (L) [15985-39-4]; Up 200; 22.2uM; MCF7; HT_HG-U133A	EPHB2 KIAA0319L PGR PARD6B FBLN1 EXOG SHANK1 WSCD1 PAICS VPS13D PRKCE	1.57e-06	192	207	11	2831_UP
Drug	Catechin-(+,-) hydrate [7295-85-4]; Up 200; 13.8uM; MCF7; HT_HG-U133A	EPHB2 KIAA0319L ABCG4 NF1 DMXL2 ANK1 TEX15 VPS13D PRKCE WDFY3 OSMR	2.01e-06	197	207	11	3351_UP
Drug	Metyrapone [54-36-4]; Down 200; 17.6uM; HL60; HT_HG-U133A	ZBTB20 SEC24A KIAA0319L NF1 SYNJ2 EXOG FLNB HSPA4L ATP8B2 ARL4C VCAN	2.01e-06	197	207	11	3070_DN
Drug	Bacampicillin hydrochloride [37661-08-8]; Down 200; 8uM; MCF7; HT_HG-U133A	CYP17A1 MAML1 EMSY PARD6B FBLN1 NECTIN1 ROBO3 WSCD1 MUC5B MUC6	1.20e-05	194	207	10	4417_DN
Drug	Phentolamine hydrochloride [73-05-2]; Down 200; 12.6uM; MCF7; HT_HG-U133A	SREBF2 MAML1 BCL2L2 PARD6B FBLN1 NF1 VPS13D ARNT PRKCE WDFY3	1.31e-05	196	207	10	3971_DN
Drug	Scopolamin-N-oxide hydrobromide [6106-81-6]; Down 200; 10uM; MCF7; HT_HG-U133A	CEACAM6 WNK1 EMSY FBLN1 NF1 SYNJ2 VPS13D PRKCE WDFY3 OSMR	1.37e-05	197	207	10	5436_DN
Drug	Pseudopelletierine hydrochloride [6164-62-1]; Up 200; 21uM; HL60; HG-U133A	ZBTB20 CEACAM6 CCDC15 USF2 LAMP2 ARL4C ARHGEF40 PDCL AGRN KDM4B	1.37e-05	197	207	10	1774_UP
Drug	Hydralazine hydrochloride [304-20-1]; Down 200; 20.4uM; MCF7; HT_HG-U133A	EPHB2 CEACAM5 EMSY FBLN1 NECTIN1 PPP1R9A GABBR2 VPS13D ARNT NFAT5	1.43e-05	198	207	10	3621_DN
Drug	Paromomycin sulfate [1263-89-4]; Up 200; 5.6uM; MCF7; HT_HG-U133A	TMPRSS15 KIAA0319L PARD6B ABCG4 NECTIN1 UPK3A DMXL2 TEX15 VPS13D PRKCE	1.43e-05	198	207	10	3356_UP
Drug	Acetaminophen [103-90-2]; Up 200; 26.4uM; MCF7; HT_HG-U133A	CEACAM5 MAP2 CYP17A1 CEACAM6 BCL2L2 NF1 NECTIN1 WSCD1 PAICS WDFY3	1.49e-05	199	207	10	5384_UP
Drug	Spironolactone [52-01-7]; Down 200; 9.6uM; PC3; HT_HG-U133A	TMPRSS15 RYR2 FBLN1 NF1 USF2 XRCC1 VPS13D VCAN WDFY3 OSMR	1.49e-05	199	207	10	5781_DN
Drug	CdAMP	ABCG2 POLA1 TMEM132D	2.52e-05	7	207	3	CID000168074
Drug	Methamphetamine	MAP2 SEC24A BCL2L2 EMSY FCGBP ST8SIA6 SYNJ2 AHNAK ZBTB40 ABCG2 FLNB CACNA2D1 EP400 PPP1R9A LAMP2 DEPDC1 XRCC1 CUBN TECTA GABBR2 VPS37B CREM APPL2 TIMP1 P2RX6 LGI3 PRKCE NFAT5 AGRN	2.90e-05	1401	207	29	ctd:D008694
Drug	AC1L1CRO	BCL2L2 F8 ODC1 XRCC1 PRKCE	3.01e-05	40	207	5	CID000002029
Drug	(E)-non-5-en-4-one	PGR DECR1 OPLAH	4.01e-05	8	207	3	CID005287534
Drug	Amitryptiline hydrochloride [549-18-8]; Down 200; 12.8uM; HL60; HT_HG-U133A	KIAA0319L EMSY NF1 SYNJ2 DMXL2 VPS13D C2CD3 PDCL ENG	5.84e-05	188	207	9	1865_DN
Drug	Apigenin [520-36-5]; Down 200; 14.8uM; MCF7; HT_HG-U133A	NEDD4 PSME4 AGFG1 EXOG NPAT PPWD1 CREM WDFY3 NFAT5	5.84e-05	188	207	9	3257_DN
Drug	Mometasone furoate [83919-23-7]; Down 200; 7.6uM; PC3; HT_HG-U133A	NF1 SYNJ2 ZBTB40 USF2 PPP1R9A MUC5B GABBR2 VCAN SERPIND1	5.84e-05	188	207	9	5116_DN
Drug	Promazine hydrochloride [53-60-1]; Up 200; 12.4uM; PC3; HT_HG-U133A	MAML1 ACTN2 ABCA8 CEACAM1 ABCG4 FOXRED2 ASIC4 ENG AGRN	6.09e-05	189	207	9	4308_UP
Drug	Lidocaone hydrochloride [73-78-9]; Down 200; 14.8uM; MCF7; HT_HG-U133A	EPHB2 TMPRSS15 WNK1 FBLN1 AHNAK NECTIN1 ROBO3 MUC5B KDM4B	6.34e-05	190	207	9	4421_DN
Drug	Phenformin hydrochloride [834-28-6]; Down 200; 16.6uM; PC3; HT_HG-U133A	KIAA0319L CEACAM6 ACTN2 WNK1 NRP1 AGFG1 EXOG NFAT5 KDM4B	6.60e-05	191	207	9	4283_DN
Drug	Calycanthine [595-05-1]; Up 200; 11.6uM; MCF7; HT_HG-U133A	KIAA0319L PGR FBLN1 NF1 SYNJ2 ANK1 TEX15 PRKCE AHNAK2	7.15e-05	193	207	9	2764_UP
Drug	forskolin; Up 200; 50uM; HL60; HG-U133A	TMPRSS15 WNK1 USF2 NPAT ANXA7 ARHGEF40 ARNT VCAN ENG	7.15e-05	193	207	9	783_UP
Drug	Rolipram [61413-54-5]; Up 200; 14.6uM; MCF7; HT_HG-U133A	KIAA0319L CEACAM1 NF1 ATP8B2 ARL4C VPS13D OSMR KDM4B AHNAK2	7.74e-05	195	207	9	5330_UP
Drug	Estriol [50-27-1]; Up 200; 13.8uM; MCF7; HT_HG-U133A	EPHB2 MORN1 WNK1 CEACAM1 ABCG4 NF1 ROBO3 PRKCE OSMR	8.05e-05	196	207	9	3563_UP
Drug	Chlorzoxazone [95-25-0]; Up 200; 23.6uM; MCF7; HT_HG-U133A	MORN1 ABCA8 PGR PARD6B WSCD1 PPP1R9A TEX15 CUBN GABBR2	8.05e-05	196	207	9	2263_UP
Drug	Fluoxetine hydrochloride [59333-67-4]; Up 200; 11.6uM; MCF7; HT_HG-U133A	SREBF2 ROBO3 WSCD1 PPP1R9A MUC5B GABBR2 LPCAT3 PRKCE OSMR	8.05e-05	196	207	9	3314_UP
Drug	Fluvastatin sodium salt [93957-55-2]; Down 200; 9.2uM; HL60; HT_HG-U133A	KIAA0319L RYR2 NF1 EXOG USF2 ATP8B2 VPS13D ARNT NFAT5	8.05e-05	196	207	9	3032_DN
Drug	Torsemide [56211-40-6]; Up 200; 11.4uM; MCF7; HT_HG-U133A	TMPRSS15 CYP17A1 PARD6B SHANK1 WSCD1 RAG2 GABBR2 TEK VPS13D	8.05e-05	196	207	9	3517_UP
Drug	Aztreonam [78110-38-0]; Up 200; 9.2uM; MCF7; HT_HG-U133A	PGR CEACAM1 PARD6B FBLN1 SYNJ2 NECTIN1 WSCD1 DMXL2 MUC6	8.05e-05	196	207	9	2282_UP
Drug	Zuclopenthixol hydrochloride [633-59-0]; Down 200; 9.2uM; HL60; HT_HG-U133A	RYR2 NRP1 NF1 AHNAK AGFG1 ARL4C VPS13D ARHGEF40 AGRN	8.05e-05	196	207	9	2936_DN
Drug	Midodrine hydrochloride [3092-17-9]; Up 200; 13.8uM; MCF7; HT_HG-U133A	EPHB2 SEC24A KIAA0319L WNK1 CEACAM1 PARD6B NF1 AHNAK PPP1R9A	8.05e-05	196	207	9	2250_UP
Drug	PF-01378883-00 [351320-41-7]; Up 200; 10uM; MCF7; HT_HG-U133A	EPHB2 MORN1 CYP17A1 PTPRB NECTIN1 EXOG ANK1 AGRN MUC6	8.05e-05	196	207	9	6363_UP
Drug	pG-G-G	MAP2 PKD1	8.23e-05	2	207	2	CID000196311
Drug	4-fluoroacetophenone	PGR DECR1	8.23e-05	2	207	2	CID000009828
Drug	AC1L3XJ6	F8 EXOG	8.23e-05	2	207	2	CID000096931
Drug	norgallopamil	DECR1 CACNA2D1	8.23e-05	2	207	2	CID000130026
Drug	Loracarbef [121961-22-6]; Down 200; 10.8uM; HL60; HT_HG-U133A	CYP17A1 NRP1 SYNJ2 ARL4C VPS13D ARNT APPL2 NFAT5 KDM4B	8.37e-05	197	207	9	2970_DN
Drug	Pyrazinamide [ 98-96-4]; Up 200; 32.4uM; MCF7; HT_HG-U133A	CEACAM5 MORN1 KIAA0319L RYR2 NF1 PIGR PPP1R9A ARNT PRKCE	8.37e-05	197	207	9	2839_UP
Drug	rofecoxib; Down 200; 10uM; HL60; HG-U133A	WNK1 CEACAM1 ZBTB40 SLC52A2 USF2 COG4 COL5A3 PRKCE KDM4B	8.37e-05	197	207	9	371_DN
Drug	Quipazine dimaleate salt [4774-24-7]; Up 200; 9uM; MCF7; HT_HG-U133A	KIAA0319L SREBF2 NF1 NPAT WSCD1 PPP1R9A VPS13D ARHGEF40 PRKCE	8.37e-05	197	207	9	2782_UP
Drug	nordihydroguaiaretic acid; Up 200; 1uM; ssMCF7; HG-U133A	PGR NF1 PSME4 SYNJ2 EXOG MGA TEX15 NFAT5 KDM4B	8.37e-05	197	207	9	415_UP
Drug	Trichlorfon [52-68-6]; Up 200; 15.6uM; MCF7; HT_HG-U133A	KIAA0319L BCL2L2 PGR PARD6B NF1 ZBTB40 ARL4C ARNT AHNAK2	8.37e-05	197	207	9	1675_UP
Drug	Harmaline hydrochloride dihydrate [6027-98-1]; Down 200; 14uM; HL60; HT_HG-U133A	BCL2L2 NRP1 FBLN1 NF1 SYNJ2 EXOG ATP8B2 AGRN KDM4B	8.37e-05	197	207	9	2149_DN
Drug	CP-863187 [668981-07-5]; Down 200; 10uM; PC3; HT_HG-U133A	SNX3 WNK1 NRP1 NF1 HSPA4L PPWD1 APPL2 LPCAT3 UBA6	8.37e-05	197	207	9	7512_DN
Drug	Succinylsulfathiazole [116-43-8]; Up 200; 11.2uM; MCF7; HT_HG-U133A	EPHB2 KIAA0319L PIGR EXOG ROBO3 PPP1R9A GABBR2 ARL4C VPS13D	8.37e-05	197	207	9	2821_UP
Drug	Beta-Escin [11072-93-8]; Up 200; 3.2uM; HL60; HT_HG-U133A	EPHB2 TMPRSS15 MORN1 CEACAM6 NRP1 PTPRB PIGR CREM CSPG4	8.37e-05	197	207	9	2194_UP
Drug	0173570-0000 [211245-44-2]; Up 200; 1uM; MCF7; HT_HG-U133A	CYP17A1 MAML1 WNK1 PGR NF1 RAG2 DMXL2 MUC5B PRKCE	8.37e-05	197	207	9	4715_UP
Drug	Clemizole hydrochloride [1163-36-6]; Down 200; 11uM; MCF7; HT_HG-U133A	SREBF2 WNK1 RYR2 USF2 CREM LPCAT3 WDFY3 KDM4B PUS7L	8.37e-05	197	207	9	2301_DN
Drug	Furosemide [54-31-9]; Down 200; 12uM; PC3; HT_HG-U133A	EPHB2 ZBTB20 SEC24A FBLN1 AHNAK ZBTB40 MUC5B CREM ARNT	8.37e-05	197	207	9	4503_DN
Drug	Lansoprazole [103577-45-3]; Down 200; 10.8uM; PC3; HT_HG-U133A	CYP17A1 NEDD4 FBLN1 SLC52A2 USF2 PPP1R9A GABBR2 C2CD3 PUS7L	8.37e-05	197	207	9	7306_DN
Drug	Tiabendazole [148-79-8]; Down 200; 19.8uM; HL60; HT_HG-U133A	ZBTB20 CYP17A1 EMSY NRP1 NF1 CREM ARL4C VPS13D AGRN	8.37e-05	197	207	9	2479_DN
Drug	Prilocaine hydrochloride [1786-81-8]; Up 200; 15.6uM; PC3; HT_HG-U133A	CEACAM5 MORN1 KIAA0319L ACTN2 ECM2 CUBN GABBR2 ARHGEF40 ARNT	8.37e-05	197	207	9	3727_UP
Drug	Aconitine [302-27-2]; Up 200; 6.2uM; MCF7; HT_HG-U133A	KIAA0319L RYR2 FBLN1 NF1 AHNAK ASIC4 USF2 PAICS MUC6	8.37e-05	197	207	9	6797_UP
Drug	raloxifene hydrochloride; Up 200; 0.1uM; MCF7; HG-U133A	FBLN1 NF1 COL5A3 TEK VPS13D ARNT NFAT5 AGRN PUS7L	8.37e-05	197	207	9	202_UP
Drug	isosorbide	BCL2L2 EXOG CACNA2D1	8.48e-05	10	207	3	CID000012597
Drug	indanestrol	PGR POLA1 ODC1	8.48e-05	10	207	3	CID000156224
Drug	Gestodene	F8 PGR SERPIND1 PROS1	8.48e-05	26	207	4	ctd:C033273
Drug	Methylatropine nitrate [52-88-0]; Up 200; 11uM; MCF7; HT_HG-U133A	CEACAM5 BEST2 CYP17A1 FBLN1 PTPRB PIGR NAALADL1 ECM2 CSPG4	8.70e-05	198	207	9	6495_UP
Drug	Sulfadimethoxine [122-11-2]; Down 200; 12.8uM; MCF7; HT_HG-U133A	KIAA0319L SREBF2 FOXRED2 NF1 USF2 ATP8B2 ARNT PDCL OSMR	8.70e-05	198	207	9	3441_DN
Drug	(1)-Nipecotic acid [498-95-3]; Down 200; 31uM; PC3; HT_HG-U133A	CYP17A1 KIAA0319L SREBF2 CEACAM6 NRP1 FBLN1 NF1 ZBTB40 XRCC1	8.70e-05	198	207	9	7296_DN
Drug	Isocarboxazid [59-63-2]; Up 200; 17.2uM; MCF7; HT_HG-U133A	EPHB2 MORN1 ADGRB3 WNK1 PGR PARD6B DMXL2 MUC5B WDHD1	8.70e-05	198	207	9	4706_UP
Drug	Etidronic acid, disodium salt [7414-83-7]; Up 200; 16uM; MCF7; HT_HG-U133A	BEST2 PARD6B FOXRED2 NF1 WSCD1 SLC2A9 TEX15 GABBR2 AHNAK2	8.70e-05	198	207	9	3325_UP
Drug	Tridihexethyl chloride; Down 200; 11.4uM; HL60; HT_HG-U133A	CYP17A1 KIAA0319L F8 BPNT2 NF1 SYNJ2 FLNB ARNT KDM4B	8.70e-05	198	207	9	2964_DN
Drug	Mephenesin [59-47-2]; Up 200; 22uM; MCF7; HT_HG-U133A	EPHB2 MAP2 CEACAM1 PARD6B PIGR ANK1 SLC2A9 TEX15 KDM4B	8.70e-05	198	207	9	2304_UP
Drug	Alfaxalone [23930-19-0]; Up 200; 12uM; HL60; HT_HG-U133A	EPHB2 CEACAM6 ACTN2 RYR2 ABCG4 AHNAK GABBR2 PRKCE ENG	8.70e-05	198	207	9	3135_UP
Drug	Nifenazone [2139-47-1]; Up 200; 13uM; MCF7; HT_HG-U133A	BEST2 PGR FBLN1 NF1 PIGR AHNAK TEX15 VCAN CSPG4	8.70e-05	198	207	9	2285_UP
Drug	Nifenazone [2139-47-1]; Down 200; 13uM; HL60; HG-U133A	CEACAM5 ACTN2 NF1 USF2 CREM VPS13D ARNT PDCL PUS7L	9.04e-05	199	207	9	1439_DN
Drug	Atovaquone [95233-18-4]; Up 200; 11uM; PC3; HT_HG-U133A	TMPRSS15 ZBTB20 CEACAM6 WNK1 NRP1 NF1 AHNAK ECM2 TEX15	9.04e-05	199	207	9	4201_UP
Drug	Yohimbinic acid monohydrate [27801-27-2]; Down 200; 11.2uM; HL60; HT_HG-U133A	CYP17A1 BCL2L2 NRP1 SYNJ2 UPK3A USF2 FLNB PAICS KDM4B	9.04e-05	199	207	9	2147_DN
Drug	Mafenide hydrochloride [138-37-4]; Up 200; 18uM; PC3; HT_HG-U133A	CEACAM6 ACTN2 RYR2 COL21A1 ANK1 CUBN GABBR2 CREM VCAN	9.04e-05	199	207	9	5079_UP
Drug	Glipizide [29094-61-9]; Down 200; 9uM; PC3; HT_HG-U133A	EPHB2 ZBTB20 SREBF2 FBLN1 SYNJ2 XRCC1 CREM ARNT LPCAT3	9.04e-05	199	207	9	6645_DN
Drug	Neomycin sulfate [1405-10-3]; Down 200; 4.2uM; HL60; HG-U133A	CEACAM5 TSC22D1 PIGR NPAT FLNB EP400 VPS37B P2RX6 PDCL	9.04e-05	199	207	9	1383_DN
Drug	Vitexin [3681-93-4]; Up 200; 9.2uM; PC3; HT_HG-U133A	TMPRSS15 RYR2 FOXRED2 NF1 PTPRB AHNAK CREM VCAN MUC6	9.40e-05	200	207	9	4588_UP
Drug	Clomipramine hydrochloride [17321-77-6]; Up 200; 11.4uM; MCF7; HT_HG-U133A	EPHB2 CEACAM5 ZBTB20 CYP17A1 FBLN1 NF1 ROBO3 ATP8B2 OSMR	9.40e-05	200	207	9	3182_UP
Drug	Fenoldopam	ECM2 TIMP1 VCAN ENG PROS1	1.99e-04	59	207	5	ctd:D018818
Drug	AC-474	PGR DECR1 FLNB SERPIND1 PROS1	1.99e-04	59	207	5	CID000002999
Drug	adenosine, 2'-deoxy	EXOG TARS1 ODC1 VCAN	2.21e-04	33	207	4	CID000100053
Drug	Triton X-114	CD109 NCL POLK NPAT POLA1 RPSA TMEM132D CSPG4	2.24e-04	177	207	8	CID000024775
Drug	IAA-94	GAK BEST2 RYR2 PKD1 CACNA2D1	2.33e-04	61	207	5	CID000003667
Drug	AC1L4MQE	DECR1 TMEM132D	2.45e-04	3	207	2	CID000159921
Drug	1,4-dibromobutan-2-ol	DECR1 TMEM132D	2.45e-04	3	207	2	CID000029570
Drug	Gscosg	GGT5 DECR1	2.45e-04	3	207	2	CID000174160
Drug	NSC-381858	DECR1 VCAN	2.45e-04	3	207	2	CID000343067
Drug	AC1L19G4	DECR1 EXOG	2.45e-04	3	207	2	CID000000532
Drug	AC1MPBWG	DECR1 POLA1	2.45e-04	3	207	2	CID003382771
Drug	matairesinol	CYP17A1 TMEM132D ENG	2.50e-04	14	207	3	CID000119205
Drug	hematoxilina	CEACAM5 MAP2 NCL F8 PGR WDR20 UPK3A TIMP1	2.80e-04	183	207	8	CID000010603
Drug	F0447-0125; Down 200; 10uM; PC3; HT_HG-U133A	EPHB2 F8 AHNAK USF2 WSCD1 AGRN KDM4B AHNAK2	2.91e-04	184	207	8	6429_DN
Drug	AC1OAGFW	SNX3 CEACAM1 DECR1 ANK1 HSPA4L SBF2 CCAR1 WDFY3	2.91e-04	184	207	8	CID006857352
Drug	Tribenoside [10310-32-4]; Up 200; 8.4uM; HL60; HT_HG-U133A	ZBTB20 SREBF2 NRP1 TSC22D1 CREM ARL4C TIMP1 VCAN	2.91e-04	184	207	8	2946_UP
Drug	acetone	F8 DECR1 NECTIN1 EXOG POLK POLA1 ODC1 PDCL	3.24e-04	187	207	8	CID000000180
Drug	LY 294002; Down 200; 10uM; HL60; HT_HG-U133A	EPHB2 NF1 UPK3A USF2 FLNB VCAN WDFY3 ENG	3.36e-04	188	207	8	6186_DN
Drug	N-methyl-DL-aspartic acid	EPHB2 MAP2 RYR2 DECR1 PKD1 SHANK1 CACNA2D1 NAALADL1 RGL3 GRID2 TECTA GABBR2 CIT CREM PRKCE LRBA	3.43e-04	655	207	16	CID000004376
Drug	A 5791	CYP17A1 PGR DECR1 POLA1	3.47e-04	37	207	4	CID000003408
Drug	Ketanserin tartrate hydrate [83846-83-7]; Down 200; 7uM; PC3; HT_HG-U133A	EPHB2 SREBF2 NF1 PSME4 SYNJ2 ARNT VCAN KDM4B	3.48e-04	189	207	8	6649_DN
Drug	Thioguanosine [85-31-4]; Down 200; 12.6uM; MCF7; HT_HG-U133A	SEC24A SREBF2 NEDD4 PSME4 AGFG1 CREM VPS13D NFAT5	3.61e-04	190	207	8	2619_DN
Drug	Estradiol-17 beta [50-28-2]; Down 200; 14.6uM; PC3; HT_HG-U133A	KIAA0319L NRP1 USF2 CREM VPS13D VCAN UBA6 PDCL	3.61e-04	190	207	8	6718_DN
Drug	Mitoxantrone dihydrochloride [70476-82-3]; Up 200; 7.8uM; MCF7; HT_HG-U133A	EPHB2 KIAA0319L PTPRB SYNJ2 AHNAK ROBO3 USF2 AHNAK2	3.61e-04	190	207	8	3232_UP
Disease	Colorectal Carcinoma	MAP2 CD109 WNK1 ABCA8 NF1 ABCG2 SHANK1 GRID2 ODC1 XRCC1 CUBN ARNT CCAR1 PRKCE SDCBP2 PROS1	4.22e-05	702	208	16	C0009402
Disease	intracranial aneurysm (is_implicated_in)	PKD1 VCAN ENG	7.25e-05	12	208	3	DOID:10941 (is_implicated_in)
Disease	Early Pregnancy Loss	CEACAM5 MAP2 CEACAM6 CEACAM1 ECM2 ARNT	1.26e-04	109	208	6	C3830362
Disease	Spontaneous abortion	CEACAM5 MAP2 CEACAM6 CEACAM1 ECM2 ARNT	1.26e-04	109	208	6	C0000786
Disease	Miscarriage	CEACAM5 MAP2 CEACAM6 CEACAM1 ECM2 ARNT	1.26e-04	109	208	6	C4552766
Disease	Abortion, Tubal	CEACAM5 MAP2 CEACAM6 CEACAM1 ECM2 ARNT	1.26e-04	109	208	6	C0000822
Disease	cortical thickness	ASIC2 ATP6AP1L NRP1 LRRIQ1 COL21A1 PKD1 PLEKHA7 FLNB FAT3 PM20D1 RPSA ARL4C VPS13D ARHGEF40 VCAN DOCK7 CCAR1 TMEM108 OSMR KDM4B	1.29e-04	1113	208	20	EFO_0004840
Disease	brain connectivity measurement	ZBTB20 MAP2 ATP6AP1L NRP1 NEDD4 LRRIQ1 COL21A1 CACNA2D1 FAT3 STIL VCAN	1.38e-04	400	208	11	EFO_0005210
Disease	tumor necrosis factor beta measurement	EPHB2 ZBTB40 EPHA8	1.48e-04	15	208	3	EFO_0008308
Disease	gout, urate measurement	ABCG2 SLC2A9	1.48e-04	3	208	2	EFO_0004274, EFO_0004531
Disease	childhood trauma measurement, alcohol consumption measurement	NOMO2 WSCD1 PCDHGC5 PCDHGB1 GABBR2	1.48e-04	71	208	5	EFO_0007878, EFO_0007979
Disease	arteriovenous malformation (is_implicated_in)	TEK ENG	2.94e-04	4	208	2	DOID:11294 (is_implicated_in)
Disease	coronary artery disease	ZBTB20 MORN1 ASIC2 CD109 ABCA8 DMXL1 NRP1 NEDD4 IGSF10 ABCG2 PLEKHA7 DOCK8 RGL3 PPP1R9A TEK ARL4C TMEM132D PRKCE NFAT5 KDM4B	3.23e-04	1194	208	20	EFO_0001645
Disease	Malignant neoplasm of breast	CYP17A1 CD109 SREBF2 WNK1 ATP6AP1L EMSY PGR NEDD4 NF1 SYNJ2 ABCG2 FLNB ANK1 CUBN TECTA TEK LRBA ZNF281	6.40e-04	1074	208	18	C0006142
Disease	sciatic neuropathy (biomarker_via_orthology)	MAP2 CYP17A1 NF1 LAMP2 RPSA	6.94e-04	99	208	5	DOID:11446 (biomarker_via_orthology)
Disease	asphyxia neonatorum (biomarker_via_orthology)	MAP2 XRCC1	7.28e-04	6	208	2	DOID:11088 (biomarker_via_orthology)
Disease	transient cerebral ischemia (biomarker_via_orthology)	BCL2L2 WNK1 NF1 ANK1 XRCC1 CREM	8.92e-04	157	208	6	DOID:224 (biomarker_via_orthology)
Disease	allergic sensitization measurement	EMSY IGHV1-69D COL21A1 IGHV1-69	9.72e-04	62	208	4	EFO_0005298
Disease	Hyperuricemia	ABCG2 SLC2A9	1.01e-03	7	208	2	C0740394
Disease	neuropilin-1 measurement	NRP1 DOCK7	1.01e-03	7	208	2	EFO_0020603
Disease	hyperuricemia (implicated_via_orthology)	ABCG2 SLC2A9	1.01e-03	7	208	2	DOID:1920 (implicated_via_orthology)
Disease	colorectal cancer	CYP17A1 ADGRB3 WNK1 PARD6B SYNJ2 ZBTB40 CACNA2D1 ANK1 CUBN VCAN SBF2 LRBA	1.28e-03	604	208	12	MONDO_0005575
Disease	irritable bowel syndrome (biomarker_via_orthology)	EPHB2 RPSA	1.35e-03	8	208	2	DOID:9778 (biomarker_via_orthology)
Disease	Unilateral agenesis of kidney	FREM2 UPK3A	1.35e-03	8	208	2	C0266294
Disease	beta-defensin 119 measurement	WNK1 IGHV1-69	1.35e-03	8	208	2	EFO_0801419
Disease	sarcoma (is_implicated_in)	SREBF2 PTPRB	1.35e-03	8	208	2	DOID:1115 (is_implicated_in)
Disease	Polydactyly	ARL6 FREM2 C2CD3 TTC21B CKAP2L	1.47e-03	117	208	5	C0152427
Disease	Malignant neoplasm of prostate	EPHB2 ZBTB20 RPN2 CYP17A1 NRP1 FBLN1 POLK MGA PCDH11Y COL5A3 XRCC1 APPL2	1.51e-03	616	208	12	C0376358
Disease	neuroimaging measurement	MAP2 MFSD4B ATP6AP1L NRP1 NF1 LRRIQ1 ST8SIA6 PKD1 ABCG2 ROBO3 PLEKHA7 FAT3 PM20D1 RPSA PPWD1 VCAN KDM4B	1.59e-03	1069	208	17	EFO_0004346
Disease	hyperuricemia	ABCG2 SLC2A9 NFAT5	1.61e-03	33	208	3	EFO_0009104
Disease	joint hypermobility measurement	NEDD4 COL21A1 VCAN	1.61e-03	33	208	3	EFO_0007905
Disease	Gout	ABCG2 SLC2A9	1.72e-03	9	208	2	C0018099
Disease	Thrombophilia	F8 SERPIND1	1.72e-03	9	208	2	C0398623
Disease	acute lymphoblastic leukemia (is_marker_for)	ABCG2 CSPG4 ENG	1.76e-03	34	208	3	DOID:9952 (is_marker_for)
Disease	complement C1q subcomponent subunit C measurement	EPHB2 EPHA8	2.14e-03	10	208	2	EFO_0801492
Disease	arrhythmogenic right ventricular cardiomyopathy (is_implicated_in)	ACTN2 RYR2	2.14e-03	10	208	2	DOID:0050431 (is_implicated_in)
Disease	macrophage colony stimulating factor measurement	EPHB2 ZBTB40 EPHA8	2.25e-03	37	208	3	EFO_0008217
Disease	Cognitive impairment	RYR2 DMXL1	2.61e-03	11	208	2	HP_0100543
Disease	lipoprotein measurement, phospholipid measurement	POLK MYO1H NCAN DOCK7	3.11e-03	85	208	4	EFO_0004639, EFO_0004732
Disease	cleft palate (is_implicated_in)	NECTIN1 FLNB	3.12e-03	12	208	2	DOID:674 (is_implicated_in)
Disease	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	MGA ATF7IP	3.12e-03	12	208	2	C0023485
Disease	ascending aortic diameter	C3orf20 ATP6AP1L RYR2 COL21A1 FLNB	3.21e-03	140	208	5	EFO_0021787
Disease	obsolete_red blood cell distribution width	WNK1 F8 ATP6AP1L ST8SIA6 WDR20 SIMC1 ZBTB40 USF2 POLK ANK1 EP400 DOCK8 SCAMP3 NOL9 CIT RUVBL1 LPCAT3 HELZ2 PRKCE	3.29e-03	1347	208	19	EFO_0005192
Disease	feeling nervous measurement	CADM2 NF1 MGA CACNA2D1	3.38e-03	87	208	4	EFO_0009597
Disease	DEAFNESS, AUTOSOMAL RECESSIVE (disorder)	DMXL2 TMEM132E	3.66e-03	13	208	2	C1846647
Disease	gallbladder cancer (is_implicated_in)	CYP17A1 XRCC1	3.66e-03	13	208	2	DOID:3121 (is_implicated_in)
Disease	hepatocyte growth factor measurement	BPNT2 CACNA2D1 TMEM132D	3.70e-03	44	208	3	EFO_0006903
Disease	alcohol use disorder measurement	ZBTB20 CADM2 NF1 LRFN5 GABBR2 KDM4B	4.23e-03	214	208	6	EFO_0009458
Disease	thalamus volume change measurement	ASIC2 LRFN5	4.26e-03	14	208	2	EFO_0021496
Disease	Saldino-Noonan Syndrome	C2CD3 TTC21B	4.26e-03	14	208	2	C0036069
Disease	Prostatic Neoplasms	ZBTB20 RPN2 CYP17A1 NRP1 FBLN1 POLK MGA PCDH11Y COL5A3 XRCC1 APPL2	4.53e-03	616	208	11	C0033578
Disease	autism spectrum disorder (implicated_via_orthology)	CSDE1 SHANK1 SCAMP3 WDFY3 LRBA	4.55e-03	152	208	5	DOID:0060041 (implicated_via_orthology)
Disease	late-onset Alzheimers disease	ZNRF4 ABCA8 AHNAK OPLAH FAT3 TECTA AGRN	4.84e-03	292	208	7	EFO_1001870
Disease	Neuralgia, Supraorbital	CYP17A1 CACNA2D1	5.56e-03	16	208	2	C0038870
Disease	Neuralgia	CYP17A1 CACNA2D1	5.56e-03	16	208	2	C0027796
Disease	5-oxoproline measurement	SLC52A2 OPLAH	5.56e-03	16	208	2	EFO_0010988
Disease	Neuralgia, Atypical	CYP17A1 CACNA2D1	5.56e-03	16	208	2	C0234247
Disease	Neuralgia, Stump	CYP17A1 CACNA2D1	5.56e-03	16	208	2	C0234249
Disease	Neuralgia, Iliohypogastric Nerve	CYP17A1 CACNA2D1	5.56e-03	16	208	2	C0423712
Disease	Neuralgia, Perineal	CYP17A1 CACNA2D1	5.56e-03	16	208	2	C0423711
Disease	triiodothyronine measurement	EPHB2 PRKCE	5.56e-03	16	208	2	EFO_0008392
Disease	Paroxysmal Nerve Pain	CYP17A1 CACNA2D1	5.56e-03	16	208	2	C0751373
Disease	Nerve Pain	CYP17A1 CACNA2D1	5.56e-03	16	208	2	C0751372
Disease	Neuralgia, Ilioinguinal	CYP17A1 CACNA2D1	5.56e-03	16	208	2	C0751371
Disease	Neuralgia, Vidian	CYP17A1 CACNA2D1	5.56e-03	16	208	2	C0042656
Disease	gout, hyperuricemia	ABCG2 SLC2A9	5.56e-03	16	208	2	EFO_0004274, EFO_0009104
Disease	interferon gamma measurement	EPHB2 ZBTB40 EPHA8	5.61e-03	51	208	3	EFO_0008165
Disease	Endometrioma	PGR NRP1 FBLN1 ARNT VCAN	5.79e-03	161	208	5	C0269102
Disease	Endometriosis	PGR NRP1 FBLN1 ARNT VCAN	5.79e-03	161	208	5	C0014175
Disease	monocyte count	WNK1 GGT5 ABCG4 NF1 PKD1 NPAT FLNB ANK1 DOCK8 PM20D1 B3GNT7 VCAN ZC3HAV1L PRKCE ENG SERPIND1 DISP1 KDM4B	5.91e-03	1320	208	18	EFO_0005091
Disease	corpus callosum posterior volume measurement	CACNA2D1 PRKCE TMEM108	5.92e-03	52	208	3	EFO_0010298
Disease	Familial thoracic aortic aneurysm and aortic dissection	PKD1 VCAN ENG	6.24e-03	53	208	3	C4707243
Disease	thyroxine measurement, triiodothyronine measurement	EPHB2 VPS37B	6.27e-03	17	208	2	EFO_0005130, EFO_0008392
Disease	lipoprotein measurement	ABCA8 IGHV1-69 MYO1H DOCK7	6.59e-03	105	208	4	EFO_0004732
Disease	Hemangiosarcoma	PTPRB TEK	7.02e-03	18	208	2	C0018923

Protein segments in the cluster

Peptide	Gene	Start	Entry
GALETVNQIIVNFPS	TTC21B	196	Q7Z4L5
SFTQAIPAGQLLQTA	nan	41	Q6ZS92
FQVNPFLTQVTGRIF	CAPZA3	176	Q96KX2
TVPATQQLFSQGNTF	ARNT	576	P27540
VNTIAGVPAATFQSI	EP400	2636	Q96L91
ARSLVPQVSQATGVQ	EP400	2726	Q96L91
TVFQLRQPSFQGSTF	BEST2	351	Q8NFU1
AASNSLQVATFVGPV	ABCG4	526	Q9H172
VDPNGQGTVTFQSFI	ACTN2	801	P35609
FEATAPTLLGQVFQV	ARHGEF40	21	Q8TER5
NEFVNTVPTIGFNTE	ARL4C	36	P56559
PVFTETNTLENLGAQ	VCAN	1791	P13611
QLVRAGQPATAFSQQ	CSPG4	1176	Q6UVK1
PTSAFSQFQIDQGEV	CSPG4	1996	Q6UVK1
IPASDGVQNFFQIVS	ADGRB3	636	O60242
FTATAVSQPAALGVQ	CCAR1	16	Q8IX12
APSFQQEASRQGLTV	CDCP1	521	Q9H5V8
FPATTFQDIQRGVTS	COG4	501	Q9H9E3
NQNVATEDGFTPLAV	ANK1	136	P16157
TQELFIPNITVNNSG	CEACAM5	281	P06731
VEVFIPVSQGNTNGF	ABCG2	6	Q9UNQ0
QVSTGDTRIFFVNPA	AGRN	106	O00468
QAGPQSAQLSVFQTA	CCNJ	251	Q5T5M9
TPGSAQQRFTQVSDE	BCL2L2	71	Q92843
GVFVQEVTQNSPAAR	AHNAK	31	Q09666
FSISDKQRPGQQVAT	CSDE1	491	O75534
NAQSQNILPTIGFSI	ARL6	41	Q9H0F7
VTQVTQGTIRPAANF	ANXA7	171	P20073
GEVFNIVSQQSTARP	DMXL2	816	Q8TDJ6
VGQIFNTSRNASPEA	ADGRG7	186	Q96K78
SVFQQPVIFLGADVT	AGO3	586	Q9H9G7
QQTIHVFQVTPEGTF	DET1	236	Q7L5Y6
GEVFNIVSQQSTARP	DMXL1	796	Q9Y485
TTSSFVQIQNGVAPL	DISP1	1301	Q96F81
VFAASSNSFPVSIVQ	CIT	1776	O14578
SNSFPVSIVQVNSAG	CIT	1781	O14578
LQASNTIEPGQQSFV	ENG	461	P17813
TIEPGQQSFVQVRVS	ENG	466	P17813
RFVGNAQNTLAQPTV	ATP8B2	1071	P98198
PGFQTFVATQEQRLT	ASIC2	266	Q16515
VTAALQSVFPQAELG	CFAP206	156	Q8IYR0
PALGVSVTFNGQVFQ	MUC5B	5191	Q9HC84
VTVSNNIALIQPGFS	RAG2	6	P55895
NTPQLADIVATGFSV	NOMO3	396	P69849
PFSVNFENVNATNAI	OSMR	336	Q99650
QNGFIPSNEVSLAAI	PARD6B	331	Q9BYG5
NTFDNIFIAPVGIST	SERPIND1	146	P05546
FQRAQVLATSGIISP	LRFN5	216	Q96NI6
AVSPNFSQGSAIIIA	NPAT	921	Q14207
AQATVNFRIHPGQTV	PM20D1	356	Q6GTS8
EVAQGSPFSVNVQLL	MORN1	226	Q5T089
FPQQVGQFTGSSAAV	MAML1	681	Q92585
TSNGLQITPFGQSVR	MUC6	126	Q6W4X9
VFGFTISQGQPAQDI	NOL9	151	Q5SY16
NTPQLADIVATGFSV	NOMO2	396	Q5JPE7
QQSAFIEGFTVPSAV	PTPRB	896	P23467
NARLTIFGNSAVSQP	NEDD4	721	P46934
RVASPLDQNGSFNVV	MGA	366	Q8IWI9
STFAFAAGQTTPQII	SBF2	1011	Q86WG5
RFLFVVAAATGVQSQ	IGHV1-69	6	P01742
QVITLPQNSITLFGN	KIAA0319L	511	Q8IZA0
SPAGVADRNFTLQVQ	HMCN2	3396	Q8NDA2
QETPDQVGSQRFSVN	PRKCE	226	Q02156
TQELFIPNITVNNSG	CEACAM6	281	P40199
PGTIRIFSNQVTATF	TMPRSS15	301	P98073
AQPETQATSFGNVLF	FREM2	2956	Q5SZK8
QGSIISAQVSPTRNF	FSIP2	421	Q5CZC0
FEIQAVNGVTDQSPF	EPHB2	406	P29323
SVTFVDGNNPFQAVQ	GRID2	66	O43424
AFTNKPNVFTVVTRG	FLNB	1341	O75369
VSVSPQSGVVFAQRA	PCDHGB1	501	Q9Y5G3
NDNAPTFQSSVLRVG	PCDHGC5	236	Q9Y5F6
GVSIFLVSAQNPTTA	MUCL1	11	Q96DR8
SNFGPEVTRQQTIQL	DEPDC1	61	Q5TB30
PIQQVVTGQSGLFTQ	KDM4B	71	O94953
AVEAQIRSFGQTPSQ	LRBA	2466	P50851
TNPRFTGTIASFNIN	LPCAT3	326	Q6P1A2
NTFDLRVQPFNVTQG	LAMP2	346	P13473
VFQGNQDSFTPVVNS	F8	2301	P00451
IGFQPQLTEFQVSLQ	EXOG	256	Q9Y2C4
AQLPQVSCVQSRFVG	LRRC29	201	Q8WV35
VSPGFQTFVSCQEQR	ASIC4	271	Q96FT7
QSFNPSIEVQTLGEA	EPHA10	541	Q5JZY3
QLGIIVSDFQPSSQA	MED10	21	Q9BTT4
SVLFVATGLSVPNQV	FOXRED2	176	Q8IWF2
GASPTVRATVAQFNT	RGL3	286	Q3MIN7
RFLFVVAAATGVQSQ	IGHV1-69D	6	A0A0B4J2H0
QVALQTFGNQTTIIP	BPNT2	251	Q9NX62
VQGSPSSQEQQVTLF	NFAT5	1361	O94916
ENVLNGSVPVSQFEI	POLA1	1121	P09884
LQAPTDQRGVTFNLS	HIDE1	61	A8MVS5
QQVTTVTFQDLPGCV	LRRIQ1	796	Q96JM4
VGPTFQDLATNVNRN	MFSD4B	16	Q5TF39
TEPTTAFNLFVGNLN	NCL	301	P19338
FQGNTNPTDVVVAVF	NRP1	381	O14786
GVPNESQALSQRFTF	PGR	661	P06401
PASQANIIFDITEGN	FBLN1	626	P23142
VINNAAGNFISPTER	DECR1	141	Q16698
NTFTAVFQSQEAPAQ	CUBN	2896	O60494
QIQFHTGFVPRNATT	GAK	666	O14976
AVVQPTAVNISANGF	CD109	1236	Q6YHK3
VVAIGSPFALQNTVT	HTRA3	256	P83110
VAANPSGVDFLIFQV	IGSF10	646	Q6WRI0
QLSPTHQINGFFTIV	C2CD3	136	Q4AC94
PALQFSATVGVNASV	C2CD3	1221	Q4AC94
TTVNQGPLEVAQVFL	DOCK7	2031	Q96N67
PVGSVSFQNISSNVL	DOCK8	1686	Q8NF50
TGTLPVFNITGQFEN	CACNA2D1	461	P54289
TQELFIPNITVNNSG	CEACAM1	281	P13688
ATNGVAETNRSVFPL	LINC00322	206	Q6ZN03
FTVTTKNQNRGNPAV	FCGBP	2916	Q9Y6R7
VSAVQPNIANFGRSL	FNIP1	986	Q8TF40
DPSQVLVFGIISSQN	C3orf20	706	Q8ND61
NGQSIDISFPVFVAV	CYP17A1	161	P05093
SGTRFVPQQTSLVQA	EPHA8	381	P29322
GFQQFLQSLQPRTTE	DDX11L8	531	A8MPP1
RITSGNPQNFFAINI	FAT3	1186	Q8TDW7
GSQGQFPLTQNVTVV	CADM2	21	Q8N3J6
SVINGSQVVTFANPQ	COL21A1	326	Q96P44
QTQRPFFLNVVQAVS	GGT5	551	P36269
NQTALQAVTPITSFG	APPL2	391	Q8NEU8
RQLGIQQTTVFTPVA	ECM2	51	O94769
VTNQPSGNVEFISVQ	ATF7IP	806	Q6VMQ6
SSFPVLTNQALQEFG	FAM166B	196	A8MTA8
GAAVSFLTRDQPNVQ	GABBR2	706	O75899
ILTGEFFQQSQRPAA	SLC2A9	436	Q9NRM0
FVRVTAVNEGGQSQP	IGFN1	916	Q86VF2
LVPQTAFTVTANAVA	EMSY	106	Q7Z589
GFVVDPNQVNVAVTR	HELZ2	2586	Q9BYK8
APSGLRSQVQFNVEV	GRAMD2B	391	Q96HH9
AVTVFQRSLTPGQFL	B3GNT7	21	Q8NFL0
ADGTQQFFVPGSQVV	CREM	216	Q03060
NDLQGSVAQVEFSPT	DNAH2	871	Q9P225
QEFAAGVFSNPAVRT	SCAMP3	316	O14828
QATSPNVFQFELGRI	RYR2	1546	Q92736
VDADGSPVNVVQLNF	COL5A3	1621	P25940
FNQTTAATVSVPQDG	COL5A3	1681	P25940
VAAASTFNGFQRPTI	ODC1	391	P11926
FLVTNFLVTPAQVQG	P2RX6	111	O15547
FGDTPLTQSIQANVT	PKD1	2236	P98161
TNPGTVVFQVIAVDN	PCDH11Y	721	Q9BZA8
VIGASSQFTRNALPA	PDCL	221	Q13371
FLQNASAVVIFNVGS	RNF150	136	Q9ULK6
GRFTPGTFTNQIQAA	RPSA	101	P08865
KRGFQEVVTPNIFNS	TARS1	366	P26639
QLSPGSNRAIFATAV	TMEM132D	681	Q14C87
NVSLGPFSTSQVVAR	TMEM132E	91	Q6IEE7
VSSFQGPLDATVVVN	SYNJ2	881	O15056
NCSAGNPNVVVTVRF	PUS7L	266	Q9H0K6
QPLFNSAVNQEGITS	SEC24A	236	O95486
ALQAQGFPRSQISTE	OPLAH	561	O14841
NSQGQLRVPVVFVTN	HDHD5	76	Q9BXW7
NRNVAVGFVPTETAT	NCAN	731	O14594
NTNGSQFFITVVPTP	PPWD1	586	Q96BP3
TNALTNGVLPAVQSF	SLC52A2	286	Q9HAB3
VTGQFSPENSEFILQ	PLEKHA7	86	Q6IQ23
SIIPNFQISQDSVGN	RNF138	116	Q8WVD3
TNTIEENFPLGTVQF	SIMC1	476	Q8NDZ2
VQNFVVSQNNTPVGT	ST8SIA6	136	P61647
SSNVNGQPVFANITL	VHLL	121	Q6RSH7
NSQGSNPVRVSFVNL	WDR20	41	Q8TBZ3
NPVRVSFVNLNDQSG	WDR20	46	Q8TBZ3
VNITAVGSFNPNVTS	TSC22D1	316	Q15714
SDGQIPANEIFVTNV	SERTAD4	256	Q9NUC0
LVSGNNTVPFAVSLV	PROS1	526	P07225
FVQLVQANTPASLVG	SDCBP2	131	Q9H190
QTPFQVAVIAGNFEL	SHANK1	381	Q9Y566
GVCPQSNVQFDFLTV	ABCA8	561	O94911
VNVLGQQTLTFEVPS	AHNAK2	5581	Q8IVF2
SVFPNNLNVAIGSSR	CCDC15	131	Q0P6D6
SSNVFGTVPVVASAQ	AGFG1	401	P52594
AVINSQGITFLPSLQ	CLDN34	151	H7C241
VNKQFVGETQSRTFP	CKAP2L	241	Q8IYA6
VFPETAQQDFQLSSG	C12orf71	151	A8MTZ7
EVQFNSAVPTNLSRG	CDK5RAP1	326	Q96SZ6
FVGTPEVNQTTLYQR	TIMP1	46	P01033
GVVSFNVLVSQFTPE	TECTA	71	O75443
TVLSPEGSAQFAAQI	PAICS	376	P22234
IFISNITQANPGIVT	UBA6	216	A0AVT1
LNGSIQQITVISPFS	UBA6	256	A0AVT1
NFSVDINNEVTSLPG	STIL	826	Q15468
AVAFSPDQQQVLSAG	WDR90	976	Q96KV7
GFINNNTFPAVVIFI	ZPLD1	81	Q8TCW7
PIVSVNTFTGRSQQI	WDFY3	3201	Q8IZQ1
GVTINSARAFPVNAV	SLC25A45	261	Q8N413
IRIGANVSNFTFAPS	RPN2	561	P04844
DARIGSFTIQNVFPQ	HSPA4L	456	O95757
VSNNTIQVHTFPEGV	WDHD1	71	O75717
FSVSPRGQLNITAVQ	ROBO3	401	Q96MS0
SGAVDPSVQRSFTQV	SREBF2	81	Q12772
QIAIPSVFVSEAASQ	ZNRF4	206	Q8WWF5
NPQILQNSVVFGTSA	POLK	276	Q9UBT6
GSAVNLQPQLASVTF	UPK3A	16	O75631
TGFQIPSQELASQID	ZNF281	801	Q9Y2X9
SVVSQRFPQNSIGAV	NF1	1391	P21359
ENQFTLTIANQGTPL	NF1	1796	P21359
QAVSALVGFATEPQF	TLNRD1	256	Q9H1K6
SNFLEIDVSNPQTVG	SNX3	26	O60493
QNVREEPAVQFNSGT	TEK	786	Q02763
RANLTNFPENGTFVV	PIGR	81	P01833
NFPENGTFVVNIAQL	PIGR	86	P01833
QTAVAITSVQQAAFG	USF2	46	Q15853
VGSSQVLVPRFLTNA	PSME4	291	Q14997
SSIAPIVIFASNRGN	RUVBL1	321	Q9Y265
NQETVQQRDTFTPSG	MAP2	416	P11137
QTQFVTVSQPGLSTF	ZBTB20	536	Q9HC78
TLIGATTENPSFQVN	WRNIP1	351	Q96S55
QGVVVVLSGFQNPFR	XRCC1	321	P18887
AFPSSLIQANVTVGT	WSCD1	261	Q658N2
FQPVGTASLQNFNIS	WNK1	2351	Q9H4A3
DQGNFSFPISVSNVV	TEX15	151	Q9BXT5
RVGLPTQQGFSSQFV	VPS37B	246	Q9H9H4
IISNNSIQAVFNPTG	ATP6AP1L	66	Q52LC2
VTSVGSVNPAENFRV	XRCC5	586	P13010
QLAGSQVFVTLPDSQ	ZBTB40	1196	Q9NUA8
GLNIPSVVNFQIIST	ZC3HAV1L	226	Q96H79
VVSTATGNFLNRLVP	TMEM108	421	Q6UXF1
APNSQTFLLVQTAQG	ZNF628	706	Q5EBL2
DVQVDNQLIGTTQPF	VPS13D	3876	Q5THJ4
NIFGEPVNLTEINSS	LRRCC1	201	Q9C099
FVAQGEVTQVPDAQA	LGI3	411	Q8N145
ISVFANATLRVQGTP	NAALADL1	446	Q9UQQ1
VNVVQGSLQFFISPG	MYO1H	986	Q8N1T3
VGVTQNFAATVLRNT	PPP1R9A	566	Q9ULJ8
TAFFLPGVHSQVVQV	NECTIN1	21	Q15223